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Abstract
Autophagy has emerged as a critical homeostatic mechanism in lymphocytes, in-
ﬂuencing proliferation and differentiation.
I sought to explore the role of autophagy in the pathogenesis of human and murine
lupus, a disease in which B cells are critical effectors of pathology.
Autophagy was assessed using multiple techniques in NZB/W and control mice,
and in patients with SLE compared to healthy controls. I evaluated the phenotype
of the B cell compartment in Vav-Atg7-/- mice in vivo, and examined human and
murine plasmablast formation following inhibition of autophagy.
I found activation of autophagy in early developmental stages of B cell develop-
ment in a lupus mouse model even before disease-onset, and which progressively
increased with age. In human disease, again autophagy was activated compared
with healthy controls, principally in naïve B cells. B cells isolated from Vav-Atg7-/-
mice failed to effectively differentiate into plasma cells following stimulation in
vitro. Similarly, human B cells stimulated in the presence of autophagy inhibition
did not differentiate into plasmablasts.
My data suggest activation of autophagy is a mechanism for survival of autoreac-
tive B cells, and also demonstrate that it is required for plasmablast differentiation,
processes that induce signiﬁcant cellular stress. The implication of autophagy in
two major pathogenic pathways in SLE suggests the potential to use inhibition of
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1.1.1 The machinery and process of autophagy
Autophagy is a highly conserved mechanism whose key function is the recycling
of intracellular constituents for the provision of energy during times of metabolic
stress. It also degrades long-lived macromolecules, defective organelles, and is ca-
pable of selective function. The genetic network governing autophagy was ﬁrst
established in the model organism S. cerevisiae, and a marked degree of conserva-
tion exists in mammalian homologous genes1. The process of autophagy consists of
three major stages: initiation, elongation and enclosure of cytoplasmic contents to
form a double-membraned autophagosome, and subsequent maturation and lyso-
somal fusion with degradation of its contents (ﬁgure 1.1).
1.1.1.1 Initiation of autophagy
The majority of experimental evidence suggests that the birthplace of nascent au-
tophagosomes is the ER, which is the major of several identiﬁed sources of mem-
brane2. The earliest pre-autophagosomal structure is the isolation membrane, which
forms at points of contact between the ER and mitochondria3. Two complexes have
been identiﬁed to be required for initiation of autophagy, and localize to the isola-











Figure 1.1: Overview of autophagy. Autophagosome nucleation occurs at the en-
doplasmic reticulum, followed by expansion and elongation, then clo-
sure of the double membraned autophagosome. Completion and re-




class III phosphoinosite 3-kinase (PI3K) complex.
The ULK1 complex consists of ULK1 (the mammalian homologue of yeast Atg1),
mAtg13, FIP200, and Atg1014. It is of importance as it integrates signals from the
metabolic master regulatory complex mechanistic target of rapamycin complex-1
(mTORC1), and the energy sensor AMP-activated protein kinase (AMPK)5. AMPK
activation in response to glucose starvation phosphorylates ULK1 at Ser317/777,
which initiates autophagosome formation. The function of the ULK1 complex in
initiating autophagy is understood to a limited degree, but FIP200 directs Atg16L1
to the isolation membrane and therefore recruits the two ubiquitin-like systems (dis-
cussed in 1.1.1.2) required for elongation6. In mammals there appears to be a degree
of functional redundancy between ULK1 and its homologue ULK27.
The second major complex involved in initiation of autophagosome formation
is the class III PI(3)K complex, which consists of Vps34, p150, beclin-1, and vari-
able beclin-1 binding partners including Atg14L, activating molecule in beclin-1-
regulated autophagy 1 (AMBRA1), rubicon, Bif-1, and UV radiation resistance-associated
gene (UVRAG)8. Beclin-1 provides an interface between autophagy and cell death
by binding via its BH3 domain to Bcl-2 or BclXL, or through its caspase-dependent
cleavage. Vps34 phosphorylates phosphatidylinositol on the 3΄position of its ring,
to generate phosphatidylinositol-3-phosphate (PI3P), which localizes to regions of
the ER upon induction of autophagy9, and acts as a docking site for FYVE- and
PX- domains10. As with the ULK1 complex, there is limited understanding of how
PI3P formation at nucleation sites engages the ubiquitin-like systems required for
elongation of the isolation membrane. It appears PI3P binds the double FYVE-
containing protein-1 (DFCP-1)9 and WD-repeat domain phosphatidylinosite inter-




In the Atg12 system, Atg12 is covalently conjugated to Atg5. Atg12 is ubiquitin-
like and is ﬁrst activated by Atg7 (E1-like) then transferred to Atg5 by Atg10 (E2-
like)12;13. The Atg5-12 conjugate then associates with Atg16L1, to form a multi-
meric complex14. Atg16L1 is responsible for targeting Atg5-12 to the developing
autophagosome, and subsequently speciﬁes the site of lipidation15. The Atg16L1
complex diffuses from the isolation membrane as it matures, and it is therefore an
early marker of autophagosome formation.
The second system lipidates LC3 (the mammalian homologue of yeast Atg8) by
attachment of phosphatidylethanolamine (PE)16. This conjugation system shares
the same E1-like enzyme, Atg7, but uses an alternative E2-like enzyme - Atg3. The
Atg5-12 conjugate fulﬁlls an E3-like role in transferring LC3 from Atg3 to PE17.
Following fusion with the lysosome, the protease Atg4, which initially processes
LC3 by removing the terminal arginine residue, also delipidates LC3 for subse-
quent reuse18;19. Once conjugated to PE, LC3 (denoted LC3-PE or LC3-II) becomes
membrane associated, and mediates membrane tethering and hemifusion during
the elongation process20.
Detection of autophagosome-associated LC3 has emerged as a preferred tool for
the quantiﬁcation of autophagy, as it remains the only identiﬁed protein speciﬁc for
mature autophagosomes21.
1.1.1.3 Maturation and fusion
Autophagosomes form randomly in the cytoplasm, but move along microtubules22.
The initial fusion step with endosomes requires Rab7, ESCRTSs, C-Vps, and UVRAG1;
following this, a structure called an amiphisome is formed23–25.
Autophagosome-lysosome fusion26 appears to be regulated in part by physical
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proximity; activation of autophagy by mTORC1 inhibition leads to lysosome traf-
ﬁcking towards the nucleus, where encounter with autophagosomes is more likely27.
Similarly, the lysosomal master transcription factor transcription factor EB (TFEB)
co-regulates autophagosome and lysosome biogenesis in response to nutrient star-
vation28.
Directed fusion with lysosomes requires syntaxin 17, a soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE) complex29.
Finally, lysosomal pH must be appropriate for fusion to occur, and inhibition of
lysosomal H+ATPase with agents such as chloroquine or baﬁlomycin A1 provides
a key target for pharmacological inhibition of autophagy30.
1.1.2 Selective autophagy
Autophagy may function as a non-speciﬁc bulk process, but also exhibit selectivity,
achieved by adapter proteins, that target the substrate to nascent autophagosomes.
The best-characterized adapter protein is p62, also known as sequestosome-1. p62
contains both ubiquitin and LC3-binding domains (UBA and LIR), and therefore
targets ubiquitinated substrates to the autophagosome for degradation31;32. Inter-
estingly, p62 has homeostatic functions distinct from autophagy, and its accumula-
tion in autophagy deﬁcient cells is cytotoxic and leads to tumorigenesis, in part at
least due to NF-κB activation33;34. p62 has been demonstrated to be necessary for
clearance of protein aggregates, mitochondria, and bacteria34;35.
The protein neighbour of BRCA1 (Nbr1) has also been identiﬁed as an autophagy
adapter protein36. Nbr1 is structurally homologous to p62, containing UBA and LIR
domains, and as with p62 is cleared principally via autophagy. Nbr1 is induced in
stimulated CD4+ T cells, and is required for TH2 differentiation, via regulation of































Figure 1.2: Summary of the process and regulation of autophagy. Autophagy
is broadly activated by cellular stress stimuli, leading to autophago-
some nucleation in the ER, a process requiring the ULK1 and class III
PI3K complexes. The elongation of the isolation membrane to form an
autophagosome requires two ubiquitin-like conjugation systems: the
Atg12 system and the Atg8/LC3 system. Upon reaching maturity, au-
tophagosomes fuse ﬁrst  with endosomes, and then with lysosomes,
where their contents are degraded.
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Structurally dissimilar to p62 and Nbr1 is NDP52, identiﬁed as a ubiquitin-binding
adapter for TANK1-binding kinase (TBK1) and a selective autophagy receptor. NDP52
is required for restriction of Salmonella typhimurium, and contains UBA, galectin-8,
and LIR binding domains38;39.
The selective degradation of mitochondria (‘mitophagy’), plays a critical role in
the maintenance of cellular homeostasis, as accumulation of defective mitochondria
that have undergone outer membrane permeabilization will activate apoptosis40.
Loss of mitochondrial outer membrane integrity leads to the release of cytochrome
c into the cytosol, where it induces oligomerization between apaf-1 and caspase-9,
forming the apoptosome and activating the ‘executioner’ caspases -3 and -7, which
are the terminal effectors of apoptosis41.
Mitophagy is also important in erythrocyte maturation, and in clearance of male
mitochondria following oocyte fertilization42;43. Mitophagy in reticulocytes, which
mature into erythrocytes, occurs via the adapter protein NIX, whose expression is
markedly increased in the latter stages of red cell development42;44;45. NIX, which
binds to the mitochondrial outer membrane, contains an LIR, and may therefore
recruit mitochondria into autophagosomes46. Defective mitochondria are cleared
by recruitment of the E3 ligase parkin by PTEN-induced kinase-1 (PINK1). Parkin
and PINK1 are mutated in some familial cases of Parkinson’s disease47;48.
1.1.3 Regulation of autophagy: signaling pathways
1.1.3.1 mTOR
mTOR is a serine/threonine kinase identiﬁed following the search for the target
of the immunosuppressant anti-fungal agent rapamycin, derived from Streptomyces
hygroscopicus, found on Easter Island (known locally as ‘Rapa nui’). mTOR forms
two complexes; mTORC1 and mTORC2. mTORC1 consists of mTOR, regulatory-
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associated protein of mTOR (raptor), mammalian lethal with Sec13 protein-8 (mLST8),
proline-rich Akt substrate 40kDa (PRAS40), and DEP-domain containing mTOR-
interacting protein (Deptor). mTORC2 comprises mTOR, rapamycin-insensitive
companion of mTOR (rictor), mammalian stress-activated MAP kinase-interacting
protein-1 (mSin1), protein observed with rictor 1/2 (protor 1/2), and mLST849.
mTORC1 acts to integrate signals from a variety of upstream environmental sen-
sors, including amino acid availability, cell stress, hypoxia, and growth factors.
Many of these signals regulate mTOR through the heterodimeric tuberous sclerosis
1/2 complex (TSC1/2). TSC1/2 is a GTPase activating protein for ras homologue
enriched in brain (Rheb). Rheb, in its GTP-associated form, phosphorylates and
thus activates mTORC1; TSC1/2 therefore negatively regulates mTORC1. The in-
puts into TSC1/2 include those that are inhibitory, and therefore activate mTORC1
signaling, e.g. class I PI3K via Akt, and extracellular-signal-regulated kinases 1/2
(ERK1/2), and those that activate TSC1/2, and therefore inhibit mTORC1, e.g. the
energy sensor AMPK, and the hypoxia sensor regulation of DNA damage response-
1 (REDD1). mTOR is also regulated by amino acids50 in a TSC1/2 independent
manner, through the Rag GTPases. Rag GTPases cause translocation of mTOR to
the lysosomal surface, where it is in proximity to Rheb and may thus be activated51.
Activated mTORC1 phosphorylates the translational regulators S6 kinase-1 (S6K1)
and eukaryotic translation factor 4E-binding protein-1 (4E-BP1), resulting in pro-
motion of protein synthesis. It also enhances lipid synthesis, and increases ATP
production through positive regulation of hypoxia inducible factor 1α (HIF1α)49.
mTORC1 inhibits autophagy by several mechanisms. A major mode of action
is by association with and phosphorylation of the ULK1-Atg13-FIP200 complex in-
volved in initiation of autophagy5;52–54. AMBRA1 is also phosphorylated by mTOR,














Figure 1.3: The mTOR signaling pathway. Regulatory inputs are integrated by
the TSC1/2 complex. TSC1/2 is a heterodimeric activating protein for
Rheb, which phosphorylates and activated mTORC1 in its GTP associ-
ated state. Phosphorylated mTORC1 inhibits autophagy and lysosome
biogenesis, whilst stimulating protein synthesis and cell growth.
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This results in the ubiquitination and subsequent self-association and activation of
ULK155.
mTOR signaling is an important determinant of T cell fate56, as it is required for
the metabolic demands of cell proliferation, i.e. the switch from catabolism to an-
abolism. Naïve T cells genetically deﬁcient in mTOR do not differentiate into effec-
tor subsets under polarizing conditions57. Instead, the formation of Tregs is favored.
A similar phenomenon is observed using rapamycin58.
The role of mTOR in B cell homeostasis has been much less explored, with no phe-
notypic reports of mice deﬁcient in essential mTOR signaling components. How-
ever, mTOR is activated upon BCR ligation59, and treatment of B cells in vitro with
rapamycin inhibits their proliferation following stimulation60.
1.1.3.2 AMPK
AMPK is a heterotrimeric kinase, constitutively phosphorylated by liver kinase B1
(LKB1) at Thr172 on its α-subunit. AMPK is allosterically regulated by the binding
of adenine nucleotides to its γ-subunit; AMP enhancing its activity and ATP sup-
pressing it61. AMPK therefore senses energy depletion, and its downstream effects
act in opposition to those of mTOR, by promoting efﬁcient ATP generation through
oxidative phosphorylation, inhibiting cell cycle progression, and inducing catabolic
processes such as autophagy. AMPK regulates autophagy both by opposing mTOR,
through dephosphorylation of the mTORC1 component raptor62 and TSC263, and
also, as mentioned above, by phosphorylation of ULK1 at Ser 317/7775 , leading to
its activation.
As with mTOR, AMPK has important roles in immune homeostasis64. AMPK
activation is associated with a switch away from aerobic glycolysis (the ‘Warburg
effect’), the preferential energy source for activated macrophages and effector T cell
subsets, e.g. TH17, towards mitochondrial oxidative phosphorylation and regula-
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tory e.g. Treg cell differentiation65;66.
1.1.3.3 Reactive Oxygen Species
ROS are small, unstable, highly reactive molecules formed from incomplete reduc-
tion of oxygen. ROS may act as multifunctional signaling molecules, and are pro-
duced at times of cellular stress. It has been shown that ROS activate autophagy,
at least in part by oxidizing Atg4, the protease responsible for delipidation of LC3-
PE67. Autophagy plays a key role in removal of defective and senescent mitochon-
dria (‘mitophagy’), and ROS accumulation may therefore activate this process68.
1.1.3.4 NF-kappa B
It has been reported that beclin-1 contains a binding site for the NF-κB subunit p65,
which results in its positive regulation following p65 translocation, subsequently
inducing autophagy in the Jurkat T cell line following stimulation with phorbol
myristate acetate (PMA) and ionomycin69. However, other groups have demon-
strated that p65 is dispensable for activation of autophagy in response to multiple
stimuli70;71, but instead IκB kinase (IKK), a component of the NF- κB signaling path-
way, plays a distinct and independent role in the regulation of autophagy, at least in
part by modulating Akt signaling72. Autophagy has been described as suppressed
in Ewing sarcoma cells stimulated with TNF-α, a process dependent on NF-κB, with
evidence of mediation through mTOR activation73. However, contrary ﬁndings
have been reported in HeLa cells in response to heat shock, with failure to induce
autophagy with p65 deﬁciency, leading to increased cell death74.
1.1.3.5 Glycogen synthase kinase 3
Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase, initially identiﬁed
as phosphorylating and therefore inhibiting glycogen synthase, but which also has
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a broad range of targets across cell growth and metabolism. GSK3 exists in two
isoforms, α- and β-, which are ≈95% homologous, but exhibit differing substrate
speciﬁcities75. GSK3 is constitutively active in the resting state, and broadly in-
hibits its transcription factor targets by phosphorylating serine/threonine residues
at consensus sites. GSK3 is regulated by phosphorylation (GSK3β at Ser9, -α at
Ser21) which leads to its inactivation76. Inactive GSK3 is permissive for glycogen
synthase and eukaryotic protein synthesis initiation factor-2B (eIF-2B) dephospho-
rylation and therefore glycogen and protein synthesis. GSK3 is phosphorylated by
many growth-associated stimuli, including Akt, S6K1, and p38 mitogen-activated
protein kinases (p38 MAPK)77. Activation of GSK3 has been found to be required
for serum-starvation induced autophagy, via acetylation of HIV-1 Tat interactive
protein, 60kD (TIP60), which directly phosphorylates ULK178. However, it has
also been demonstrated that pharmacological inhibition of GSK3 may lead to up-
regulation of autophagy, through increased lysosomal biogenesis caused by TFEB
translocation79.
1.1.3.6 FoxO transcription factors
The FoxO family of forkhead transcription factors regulates the expression of a
genetic network controlling cellular stress response, metabolism, and longevity80.
FoxO members also modulate autophagy, with binding sites identiﬁed on Bnip3,
LC3, and Atg1281–83. FoxOs are subject to post-translational modiﬁcation (PTM)
including phosphorylation and acetylation, which modify their subcellular localiza-
tion (nuclear or cytoplasmic), and therefore their ability to act on their target genes.
Regulatory phosphorylation is enacted by several growth factor associated kinases,
e.g. Akt, which phosphorylates FoxO3 at Thr32 and Ser253, causing binding of
chaperone proteins such as 14-3-3, and leading to its nuclear export84. However,
phosphorylation at other sites by AMPK may not result in FoxO3 translocation, but
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instead change the target gene speciﬁcity and alter the resulting transcriptional pro-
gram85. FoxO3 has been determined to be required for autophagy in cardiac and
skeletal muscle myocytes, and in haematopoietic stem cells81;82;86. Recently, vari-
ants in FOXO3 have been associated with the severity of Crohn’s disease, malaria,
and rheumatoid arthritis (RA)87.
1.1.4 Regulation of autophagy: Beclin-1, Bcl-2 and BH3 proteins
Beclin-1, introduced above, is fundamentally important for the initiation of au-
tophagy88, and beclin-1-/- mice die at an early stage of embryonic development
(E7.5 or earlier)89. Beclin-1 contains three structural domains: an N-terminus BH3
domain, which governs its interactions with Bcl-2 family members, a central coiled
coil domain (CCD), and an evolutionarily conserved domain, which is critical for
induction of autophagy90.
Autophagy is suppressed by binding of Bcl-2 or BclXL to beclin-191;92. However,
Bcl-2 may be displaced from Beclin-1 by competitive inhibition from diverse pro-
apoptotic proteins including Bnip3, Bad, Noxa, Puma, and BimEL93;94. Beclin-1
self-oligomerizes via its CCD, and this association is stabilized by Bcl-2, which may
inhibit the interaction between monomeric beclin-1 and class III PI3K95;96. Similarly,
UVRAG disrupts beclin-1 self-oligomerization and promotes autophagy.
Beclin-1 may also be subject to PTM, by either phosphorylation or ubiquitination.
Death-associated protein kinase (DAPK), a tumour suppressor protein, phosphory-
lates beclin-1 at Thr119, which leads to its dissociation from BclXL and activation of
autophagy97. Beclin-1 is K63 ubiquitinated, principally at Lys117, through TRAF6,
which promotes autophagy98. The mechanism by which autophagy is stimulated
is unclear, but may be due to altered oligomerization.
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1.2 Systemic lupus erythematosus
1.2.1 Summary
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease charac-
terized by engagement of multiple arms of the innate and adaptive immune systems
against nuclear auto-antigens. Speciﬁcally, there is prominent type I interferon pro-
duction, B cell hyperactivation, and the production of high-afﬁnity autoantibodies
which cause immune complex deposition and trigger the complement cascade re-
sulting in tissue injury. Its clinical manifestations are variable and subject to evo-
lution, and include arthralgia, arthritis, malaise and fever, rash, glomerulonephri-
tis, and neuropsychiatric disease. It is signiﬁcantly more prevalent in women (9:1),
and in those with African, South Asian, or South East Asian ancestry. An environ-
mental trigger for SLE is rarely ascertained, although there is not infrequently an
antecedent viral infection, and links have been drawn to Epstein-Barr virus (EBV).
Despite the frequently severe disease phenotype, in the vast majority of cases
no aetiological factor is indentiﬁed, and the clinical outcome is often unsatisfactory.
Over recent years there has been increasing interest in and understanding of the im-
portance of autophagy in multiple aspects of immunity, which potentially intersect
with the pathogenesis of SLE. In this introduction, I will ﬁrst outline the functional
mechanism of autophagy, and then consider, in the context of the current under-
standing of SLE, how it may allow breach of the checkpoints which exist to prevent
development of autoimmunity.
1.2.2 Epidemiology
There are considerable variations in estimates of the prevalence of SLE, and difﬁcul-
ties surrounding comparison of populations and geographical regions due to differ-
ences in diagnostic accuracy and awareness. However, the range for incidence esti-
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mates is 1-10 per 100000 per year. Prevalence estimates range from 0.2-2 per 100099.
There is a dramatic difference in incidence between the sexes, with the female:male
ratio c. 9:1; reasons for this are discussed below100;101. SLE is considerably more
common in non-European populations, occurring >5 times more frequently in Afro-
Caribbeans and twice as frequently in Asians. The peak age of onset in women is
40-49100;101.
1.2.3 The genetics of SLE
SLE represents a complex trait with a heritability (λS) of 29 assuming a population
prevalence of 0.001)102. The advent of genome-wide association studies (GWAS)
has dramatically increased the number of identiﬁed susceptibility loci (table 1.2.3),
which had previously been restricted to rare but penetrant Mendelian variants (e.g.
deﬁciency in classical complement pathway components)103or large intervals mapped
through linkage analysis. The whole-genome coverage provided by contempo-
rary genotyping platforms allows freedom from a preconceived candidate gene ap-
proach and facilitates discovery of unsuspected mechanistic associations.
Broad insights from GWAS into the genetic architecture of the SLE include the ob-
servation that a signiﬁcant number of risk loci are shared in common with other au-
toimmune diseases, and that there are considerable differences in associated (SNPs)
between racial groups, in so far as it is possible to say given the relative lack of
GWAS in Afro-Caribbean and Asian populations. As is observed in other complex
diseases (e.g. type II diabetes), the effect size of risk SNPs is small, with typical odds
ratios of between 1.15-2, and they usually occur in non-coding regions of DNA,
whose functional signiﬁcance is only starting to be appreciated104;105.
Finally, to date only a small fraction (≈10%) of the heritability of SLE is explained
by identiﬁed common variants, and this so-called ‘missing heritability’ may be due




1.2.4 The female gender bias in SLE
There is a striking difference in the prevalence of SLE between men and women,
with similar ﬁndings in murine lupus models. Sex hormones have pleiotropic and
profound effects on most aspects of immunity. In the innate immune system, oestra-
diol promotes granulocyte-macrophage colony stimulating factor (GM-CSF) induced
differentiation of dendritic cells (DCs), and DCs treated with oestrogen inhibitors
express less CD86 and major histocompatibility complex class II (MHC-II) following
stimulation with lipopolysaccharide (LPS)109. However, oestrogens may also exert
negative regulatory effects, particularly following FMS tyrosine kinase 3 (Flt3) lig-
and stimulation, on DC maturation110. As with dendritic cells, the role of oestrogens
in T cell homeostasis is nuanced, with differential effects seen as levels increase.
Lower levels of estrogen promote TH1 polarization, whereas high levels promote a
TH2 response. Very high levels of oestrogens, associated with pregnancy, can in fact
cause a dramatic reduction in thymocyte numbers and lead to thymic atrophy111.
Similarly, B cell lymphopoiesis is also inhibited by oestrogens during pregnancy112.
However, lower concentrations of oestrogen promote humoral immunity, enhanc-
ing processes that may lead to autoimmunity, e.g. modulation of clonal deletion
and class switch recombination (CSR)113.
Whilst oestrogen has pleiotropic roles in multiple immune cell types114, there is
not a clear correlation between either oestrogen levels or exogenous administration,
and SLE disease activity115.
The complement of X chromosomes acts as an additional, independent risk fac-
tor for disease. The X chromosome contains a pseudoautosomal region that encodes
multiple genes with important functions in immunity (e.g. CD40L, MECP2), vari-



























































































































































































































































































































































































































increased in males with Klinefelter’s syndrome (XXY), and in murine models with
Sry deletion on a lupus-prone background, the disease is more severe in XX mice
compared with XY-117;118.
1.2.5 The environment and SLE
The most robust evidence for environmental factors inﬂuencing the onset of SLE
is for EBV infection, and drug-induced lupus erythematosus (DILE). Antibodies
against EBV components are seen more frequently in patients with SLE than in
healthy controls, an association not observed with other common viruses119;120.
This ﬁnding is supported by experiments suggesting that molecular mimicry oc-
curs between Epstein-Barr virus nuclear antigen-1 (EBNA-1) and the nucleoprotein
Ro, which is frequently the target of antibodies in SLE121. Defective anti-EBV im-
munity is also seen in SLE patients, e.g. higher EBV viral loads associated with
CD8+ T cell exhaustion122. DILE is a well-recognized phenomenon reported with
the use of at least 50 different pharmaceuticals, classically including hydralazine,
procainamide, and methyldopa. Whilst it has many clinical features in common
with SLE, it is very rarely causes hypocomplementaemia or renal disease. Its char-
acteristic autoantibody is anti-histone, seen in the vast majority of cases123.
Other potential environment risks are less clearly established. There is likely a
weak effect for smoking at time of diagnosis (OR ≈ 1.5)124. There is some evidence
that exposure to crystalline silica may predispose towards SLE125. Associations




1.3 Checkpoints in immunity and the development of
autoimmune disease
One of the striking properties of the human immune system is the ability to respond
and adapt to an essentially unlimited variety of antigenic structures, achieved by
the production of highly variable immunoglobulin molecules and T-cell receptors
(TCRs) by the recombination of variable (V), diversity (D), and joining (J) genes dur-
ing lymphocyte development. An inevitable consequence of this random process
is the formation of self-reactive receptors which have the potential to cause autoim-
mune disease. However, in healthy individuals, these lymphocytes are deleted or
inactivated and do not proliferate and cause tissue damage. In this section I will
consider the checkpoints which exist to prevent the development of autoimmune
disease
1.3.1 Clearance of apoptotic cells
A key paradigm in the pathogenesis of SLE is that failure of the clearance of apop-
totic or necrotic cells leads to the release of nuclear constituents which subsequently
incite a pro-inﬂammatory immune response; the so called ‘waste disposal’ hypoth-
esis127. Evidence for this comes from disease associated genetic variation, animal
models, and clinical ﬁndings. Deﬁciency of components of the classical pathway of
complement activation (e.g. C1q, C4) impairs opsonization and phagocytosis of nu-
cleic acid-containing immune complexes through complement receptors103. These
immune complexes are instead hypothesized to stimulate toll-like receptors (TLRs)
in, notably, plasmacytoid dendritic cells (pDC), or activate Fc-receptors. Similarly,
defects in phagocytosis through complement receptor-3 (CR3) caused by coding
variants in integrin, α-M (ITGAM) may also be associated with SLE128. Germinal
centre (GC) macrophages in patients with SLE display impaired uptake of apoptotic
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cells, which may lead to their excessive presentation of auto-antigens to B cells un-
dergoing the GC reaction129. Mouse models with macrophages lacking the Tyro3
tyrosine kinase Mer and thus unable to phagocytose apoptotic cells develop anti-
dsDNA autoantibodies, but not overt clinical disease; however a full SLE-like phe-
notype may be induced by constitutive activation of monocytes by additional dele-
tion of the other Tyro3 members Tyro3 and Axl130;131.
1.3.2 Type I interferon
A hallmark of SLE is overproduction of type I interferon, and the major source of
this appears to be from pDCs. pDCs are specialized in the production of type I
interferons (IFN) and other pro-inﬂammatory cytokines upon stimulation of, most
relevantly, TLR -7 and -8 by single-stranded RNA (ssRNA), and 9 by unmethylated
CpG motifs132. Type I IFN serves to activate an antiviral state in multiple com-
ponents of the immune system. This includes maturation of immature myeloid
dendritic cells (mDC) to allow stimulation of CD4+ T cells and the subsequent ex-
pansion of B cells133. The type I interferon pathway is a central driving force in
SLE. This is underscored by the induction of autoimmunity as a side effect of ad-
ministration of IFN-α, the correlation between serum IFN-α levels and disease ac-
tivity in many patients134, the presence of an interferon-inducible gene signature in
SLE peripheral blood mononuclear cells, and the amelioration of disease by anti-
IFN-α antibodies135;136. pDC secrete large quantities of type I IFN after internal-
izing immune complexes containing DNA or ribonucleoprotein (RNP)137, or DNA
in association with the antimicrobial peptide LL37 (cathelicidin)138. Not only does
self-nucleic acid stimulation of TLRs drive SLE, but it also accounts for the relative
corticosteroid resistance seen in many patients139.
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1.3.3 B cell receptor formation and testing
B cells develop in the bone marrow from the common lymphoid progenitor, which
is one of the fates of the multipotent progenitor cell (the other being the common
myeloid progenitor)140. Commitment to the B cell lineage is determined at the ear-
liest stage by the transcription factors E2A, early B cell factor (EBF) , and (Pax5)141.
Pro-B cells start to express the B220 marker, recombination activating gene-1/2
(Rag1/2), and Igh DH-to-JH recombination has concluded as they enter the Pre-B(I)
stage, associated with CD19 expression. The Igh locus then undergoes VH(DH)J re-
combination until pre-B cell receptor (BCR) formation is possible (composed of IgH,
the surrogate immunoglobulin light chains VpreB and λ5, Igα, and Igβ).
During normal B cell development, Igh locus recombination frequently (up to
75% of immature B cells in humans)142 results in the production of autoreactive
BCRs, which are tested for binding to self-antigen at the transition from pre-B to
immature B stage, through pre-BCR signaling. This represents an initial tolerance
checkpoint, illustrated when deﬁciency of surrogate light chains results in the es-
cape of self-reactive B cells and the subsequent development of anti-nuclear anti-
bodies (ANA)143. Pre-BCR signaling results in allelic exclusion, so that each B cell
utilizes only one heavy and light chain allele during its lifetime.
A second central tolerance checkpoint is through receptor editing. Secondary re-
arrangement of the V regions of Igl or Igh occurs, which may result in loss of au-
toreactivity144. However, receptor editing may be only partial, or may even cause
de novo self reactivity145;146. Failure of these early central checkpoints may occur in
SLE; newly emigrant B cells from patients are more likely to be autoimmune than
those from healthy controls, even when in clinical remission147;148.
Following encounter with their cognate antigen, B cells migrate to the lymphoid
tissue and form germinal centres, structures in which somatic hypermutation (SHM)
occurs to hone the afﬁnity of the antibody response and produce either plasma cells
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or memory B cells. The germinal center reaction is abnormal in SLE, because au-
toreactive B cells do not undergo deletion but develop into plasma cells secreting
autoantibodies marked by signs of somatic mutation149. The mechanisms by which
self-reactive B cells generated by SHM are deleted are poorly understood, but it is
clear that autoimmunity may arise following dysregulation of many components
of the GC. A further tolerance checkpoint is observed to occur in humans as newly
emigrant B cells become mature naïve B cells. There is a substantial reduction in
the frequency of self-reactive B cells following this transition142. Mechanisms that
may account for this attrition include internalization of the self-antigen bound BCR,
leading in the absence of T cell help to decreased B cell activating factor receptor
(BAFF-R) expression and thus deprivation of survival signals150, and an increase
in levels of the pro-apoptotic molecule Bcl-2 like 11 (BIM)151. Once mature, B cells
become either follicular, or marginal zone subsets. Follicular B cells are resident in
the follicles of the lymph nodes or spleen, and recirculate. Marginal zone B cells are
an innate-like population resident in the splenic marginal zone.
As B cells undergo terminal differentiation into plasmablasts and then plasma
cells, they begin to secrete very large quantities of immunoglobulin, which im-
poses signiﬁcant metabolic stress on the cell. In particular, accumulation of de-
fectively folded proteins in the endoplasmic reticulum (ER) can lead to cell death.
The adaptive mechanism activated by cells to mitigate this ER stress is known as
the unfolded protein response (UPR)152. Plasma cells are dependent on the UPR
for immunoglobulin secretion, but it is dispensable for normal B cell activation,
class switching, and cytokine production153. Plasma cell differentiation is associ-
ated with up-regulation of genes promoting the UPR, notably PR-domain zinc ﬁn-
ger protein 1 (PRDM1), also known as Blimp-1, and suppression of cell cycle and
growth promotion genes, e.g. PAX5154. There is evidence that the UPR is also re-
quired at an early stage of B cell development, during Igh locus rearrangement and
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production of the BCR155. Ig gene rearrangement by necessity induces DNA dam-
age, and it is possible that the UPR is required to control the associated cellular
stress.
There is disturbed B cell subset balance in SLE. There is an overall reduction in
total B cell numbers, but the number of circulating plasmablasts (CD27++) may be
markedly increased in active disease156;157, and these can populate extra-medullary
sites such as the kidney, in which inﬂammation has lead to up-regulation of survival
factors such as CXCR12, transforming growth factor-β (TGF-β), and BAFF, forming
disorganized ectopic follicular structures158. Long-lived plasma cells in the bone
marrow enjoy resistance to many standard agents used in the treatment of SLE, in-
cluding rituximab (due of loss of the targeted antigen CD20), cyclophosphamide,
and corticosteroids159;160. There is also an increase in the novel CD5+ pre-naïve
population, which represents an intermediate stage between transitional and naïve
B cells161. The characteristics of this population are an impaired response to BAFF
and increased apoptosis, but a retained capacity to differentiate into plasma cells,
and perform anretigen presentation. There is evidence for the existence of regu-
latory subsets of B cells ‘Bregs’, which suppress immunity by provision of IL-10,
thereby promoting Treg rather than T effector polarization of T cells162. This reg-
ulatory function has been ascribed to a number of B cell subsets, but in humans a
CD19+CD24hiCD38hi transitional population was shown to produce IL-10 and in-
hibit TNF-α and IFN-γ production by T cells163. In SLE however, this population,
although not reduced in numbers, is dysfunctional and lacks suppressive effect.
1.3.4 T cell receptor formation and testing
T cell development in the thymus proceeds through positive and negative selection
stages, and in common with B cell development, strongly autoreactive cells may
be deleted at a number of checkpoints. The initial positive selection stage occurs
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when the newly formed T cell receptor (TCR) is tested for recognition of MHC as-
sociated with bound peptide, presented on cortical thymic epithelial cells (cTECs).
Should the thymocyte weakly recognize this self-peptide in the context of MHC, it
is selected to survive and undergo further development, whilst Rag expression is
suppressed, ending receptor gene rearrangement. Following positive selection of
those T cells with self-MHC restricted receptors in the thymic cortex, thymocytes
proceed to the medulla, where negative selection of those with TCRs strongly re-
active against self-antigens expressed on medullary cortical epithelial cells (mTEC)
occurs. Notably, TECs require autophagy for efﬁcient presentation of self-antigens
on MHC-II, and engraftment of Atg5-/- thymi into athymic Nude mice results in se-
vere autoimmune disease due to failure of negative selection164. Similarly other
mechanisms that result in failure of negative selection also lead to systemic autoim-
munity165. An example of such a defect is the rare disease autoimmune lymphopro-
liferative syndrome (ALPS), also known as Canale-Smith syndrome, which is asso-
ciated with splenomegaly, lymphadenopathy, and autoimmune cytopenia. ALPS
is caused by defects in Fas signaling, which results in failure of apoptosis induced
by negative selection166.
1.3.5 Anergy
Should a self-reactive receptor escape central selection processes, further mecha-
nisms exist to prevent cell activation and autoimmunity. Collectively, and in nor-
mal homeostasis, the processes which limit the proliferation of these cells lead to
either apoptosis, or a state of inertia known as anergy167. Autoreactive B cells have
substantially diminished levels of surface IgM, caused by blockade of transport of
the immunoglobulin molecules from the endoplasmic reticulum168. Another pro-
cess especially relevant to the pathogenesis of SLE is the impairment of intracellular
trafﬁcking of the endocytosed BCR and endosomal TLR9, inhibiting the synergis-
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tic signaling that results from co-stimulation of these receptors169. An alternative
inhibitory mechanism to limit the response to TLR9 and BCR co-signaling is the
induction of ERK by the BCR, which prevents TLR-induced plasma cell differenti-
ation170. Signaling pathways downstream of the BCR are also subject to inhibitory
feedback through the molecules SH2 domain-containing phosphatidylinositol 5-
phosphatases (SHIP-1), and phosphatase and tensin homologue deleted on chro-
mosome 10 (PTEN). SHIP-1 mediates the inhibitory action of the receptor FcγRIIB,
and knockout of either of these molecules leads to a systemic autoimmune disease
resembling SLE171. PTEN dephosphorylates PI3P and therefore antagonizes PI3K
signaling. PTEN is upregulated in anergic B cells, and loss of PTEN results in a
murine hyper-IgM syndrome172. PTEN is downregulated in human SLE, and may
contribute to B cell hyperresponsiveness173.
T cells also possess similar inhibitory receptor systems, for example CTLA-4 com-
petes for binding to B7 and B7.1 with CD28, and also induces Treg formation174.
CTLA-4 function is defective in SLE, and genetic variants in the CTLA-4 locus pre-
dispose to SLE175; CTLA-4 knockout leads to severe autoimmune disease in mice176.
Multiple abnormalities exist in T cell homeostasis in SLE, including in signaling,
metabolism, and effector subset balance.
In the TCR signaling complex, there is loss of the CD3ζ chain, which is replaced
by the Fc receptor-γ chain (FcRγ) with the effect that the more potent spleen tyro-
sine kinase (Syk) is activated rather than the canonical zeta-chain-associated pro-
tein kinase-70 (ZAP-70) pathway, thereby amplifying the downstream response177.
Levels of the transcription factor cAMP response element modulator-α (CREM-α)
are increased, leading to decreased expression of IL-2, but elevated IL-17A produc-
tion178. Additional effects of abnormal signaling include elevated expression of the
surface adhesion molecule CD44, and the co-signaling molecule CD154179;180.
T cells in SLE exhibit features of disordered metabolism. These include mito-
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chondrial hyperpolarization, excessive production of ROS, and relative depletion
of ATP181;182. Elevation in mitochondrial transmembrane potential (Δψm) may be
a prelude to release of cytochrome c and induction of apoptosis, but this is not in-
evitable and the increase in Δψm recapitulated by CD3/28 stimulation is reversible.
Cytokine stimulation with e.g. IL-3 and interferon-γ also increase Δψm, but inter-
estingly IL-10 increases ROS production and cell death in SLE T cells but not in
healthy controls182.
Mechanistic target of rapamycin (mTOR), a serine-threonine protein kinase that
integrates information on amino acid availability, cellular energy status, and im-
mune receptor binding, is activated in SLE183. mTOR is of great importance in the
regulation of autophagy and in this capacity will be considered separately. Activa-
tion of mTOR is associated with differentiation of T cells to effector subsets; T cell
speciﬁc mTOR deﬁciency leads to an increase in Foxp3+ (forkhead box protein 3)
regulatory T cells, which is also the case when mTOR is pharmacologically inhib-
ited by rapamycin57;58.
Whilst there has been some question whether regulatory T cells (Treg) are deﬁ-
cient or dysfunctional in SLE184, there is clear evidence that the TH17 CD4+ T cell
subset is increased, corresponding to elevated levels of the pro-inﬂammatory IL-17
cytokine family in active disease185. The IL-17 family cytokines are necessary for
severe glomerulonephritis in murine lupus, and promote survival of autoreactive
B cells186;187.
Another T cell subset dysregulated in lupus is the T follicular helper (TFH) cell
class, whose function is to provide support to GC B cells undergoing somatic hy-
permutation (SHM) and CSR, principally through the provision of IL-21. TFH cells
are required for systemic autoimmunity188, and are increased in severe disease189.
This may potentially increase the development of plasma cells producing high afﬁn-
ity IgG autoantibodies, which are a hallmark of SLE.
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1.3.6 Competition for survival factors
A regulatory mechanism distinct from suppressive receptor signaling is competi-
tion for survival factors, exempliﬁed by the B cell activating factor (BAFF) pathway
in B cells. BAFF is produced by innate immune cells, e.g. macrophages and den-
dritic cells, and its secretion is upregulated by pro-inﬂammatory stimuli such as
type I interferon signaling and TLR ligation. The BAFF receptor signals cell sur-
vival by activation of NF-κB2 and Akt, which leads to downregulation of BIM and
stimulation of cell growth through mTOR. Strong BCR ligation by auto-antigens
increases levels of BIM, and therefore increases the dependency of the autoreac-
tive cell on BAFF; these cells are therefore less well able than those without auto-
reactive receptors to compete for limiting quantities of BAFF190. In addition to an
anti-apoptotic effect, BAFF also increases the metabolic ﬁtness of B cells through
Akt, preparing them for proliferation. BAFF overexpression leads to the produc-
tion of pathogenic autoantibodies, and the development of a lupus-like disease191.
In human SLE, levels of BAFF are elevated, and this observation, along with the
supporting data provides a rationale for the inhibition of this pathway for clinical
beneﬁt. To this end, the drug belimumab, an anti-BAFF monoclonal antibody, has
been developed and used in clinical practice to ameliorate lupus disease activity190.
1.4 Autophagy and immunity
1.4.1 Autophagy and the innate immune system
1.4.1.1 Restriction of invasive pathogens
The innate immune system has harnessed autophagy for defense against invasive
microorganisms, in both a direct capacity through selective degradation, and also
in a supportive subsidiary role. One of the main mechanisms for survival of in-
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vasive intracellular bacteria e.g. group A Streptococcus or Mycobacterium tuberculo-
sis, is interference with endosomal maturation following phagocytosis, leading to
either escape into the cytosol or proliferation within vesicles. Autophagy is uti-
lized to recapture escaped bacteria, and deliver them to the lysosome for diges-
tion. The double-membraned autophagosome securely incarcerates the bacteria,
and provides resistance to evasion strategies192. Bacteria are targeted for selective
autophagy by deposition of ubiquitin, or galectin-8 on their surface38;193. However,
the identity of the E3 ubiquitin ligase responsible remains unclear. Next, autophagy
adapter molecules, including p62, Nbr1, and NDP52, target the bacterium to the au-
tophagosome via their LIR domains.
An alternative, non-canonical autophagy known as LC3-associated phagocytosis
(LAP) may also be important for pathogen restriction. LAP, distinct from canon-
ical autophagy, results in the formation of single-membraned vesicles, unlike the
double-membraned classical autophagosomes194. Decoration of phagosomes with
LC3 promotes their maturation by fusion with the lysosomal compartment. LAP
requires some, but not all of the canonical autophagy machinery195.
1.4.1.2 Innate immune signaling
The role of autophagy in innate immune signaling is complex, and it is likely to
have both inhibitory and stimulatory effects. Autophagy is generally up-regulated
by PRR engagement.
Stimulation of TLRs activates LAP in the case of TLR2194, or canonical autophagy
(TLRs 4, 7, and 9)194;196. With the exception of TLR2, autophagy induction is MyD88-
dependent196, and promotes phagosome-lysosome fusion, resulting in enhanced
microbial killing. Autophagy may also be directly induced by cytosolic DNA, ei-
ther transfected or as the result of TB infection197.
Similarly, the PRRs nucleotide-oligomerization domain 1/2 (NOD1/2), which
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recognize intracellular γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and mu-
ramyl dipeptide (MDP) respectively, also induce autophagy upon stimulation with
their ligands198;199. A consequence of this is enhanced antigen presentation on
MHC class II, as autophagosomes fuse with MHC-II loading compartments200. The
mechanism by which NOD ligands stimulate autophagy may be through direct in-
teraction with ATG16L1, as there is co-localization between NOD1/2 and ATG16L1,
and autophagy induction is independent of the downstream signaling molecules
receptor-interacting serine/threonine-protein kinase 2 (RIPK2) and NF-κB199.
Autophagy also plays an important role in antiviral immunity, and therefore po-
tentially autoimmunity. Autophagy has been identiﬁed as functional both in cyto-
plasmic and endosomal nucleic acid sensing. Cells sense cytoplasmic nucleic acids
through receptors signaling via IFN-β promoter stimulator-1 (IPS-1), localized on
the mitochondria, or stimulator of interferon genes (STING), which is ER-bound.
The principal RNA receptors, transduced by IPS-1, are melanoma differentiation
associated-5 (MDA-5) and retinoic acid inducible gene-I (RIG-I), CARD-domain he-
licases that sense long dsRNA and short RNA with 5’ppp respectively201; so called
RIG-like receptors (RLRs). Atg5-/- mouse embryonic ﬁbroblasts (MEFs), exposed to
immunostimulatory RNA, produce more type I IFN than wild type cells, and have
higher resistance to infection with vesicular stomatitis virus (VSV)202;203. Interest-
ingly, infection with the dsDNA virus herpes simplex (HSV) resulted in decreased
interferon production in the autophagy deﬁcient cells. The Atg5-12 conjugate was
seen to co-localize with IPS-1, and it may therefore act as a repressor of signaling
downstream of RLRs202. Alternatively, the accumulation of mitochondria in au-
tophagy deﬁcient cells may enhance RLR signaling through increased production
of ROS203.
Autophagy is also important for delivery of nucleic acids into signaling compart-
ments. In pDC, the response to infection with VSV was inhibited by pharmacologic
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or genetic inhibition of autophagy in vitro and vivo. Accordingly, Atg5-/- chimeric
mice were signiﬁcantly more susceptible to mortality following infection204. Au-
tophagy in human pDC is also important for production of IFN-α in response to in
vitro infection with HIV-1205. A role for LAP in response to phagocytosis of DNA-
immune complexes (DNA-IC) in pDC has also recently been demonstrated206. It
was shown that engagement of Fc-γ-receptors by immune complexes leads to dec-
oration of the phagosome with LC3, which co-localized with TLR9. Interestingly,
CpG alone does not induce LAP, highlighting a requirement for Fc-γ signaling via
an as yet undetermined pathway. Abrogation of LAP by the class III PI3K inhibitor
3-methyladenine (3-MA) or Atg5 or -7 knockdown inhibited IFN-α production in
response to DNA-IC, but NF-κB translocation induced by TNF-α is intact.
Autophagy has an important role in regulation of the inﬂammasome, which as
discussed above, is a mediator of pathology in SLE. Inhibition of autophagy has a
potentiating effect on IL-1β and IL-18 secretion in response to a variety of stimuli.
For example, macrophages deﬁcient in Atg16L1 or Atg7 produce markedly more
IL-1β following stimulation with LPS or oxidized ATP, a P2X7 receptor agonist,
but normal amounts of IL-6207. Conversely, induction of autophagy reduces IL-1β
secretion208;209. Several mechanisms have been proposed for this ﬁnding. Firstly,
pro-IL-1β, which is cleaved into its active form by caspase-1, is targeted to the au-
tophagosome for degradation208. Secondly, inﬂammasomes have been observed
to co-localize with autophagosomes, and are targeted for degradation by ubiqui-
tination via the adapter protein p62209. Finally, autophagy deﬁciency leads to the





Recognition of antigens by T cells in the context of MHC proteins is integral to the
functioning of the adaptive immune system. The classically held model is that MHC
class I presents endogenous antigens to CD8+ T cells, whereas MHC class II presents
exogenous antigens to CD4+ T cells. To this end, the mechanisms for processing and
loading of antigens differ accordingly; MHC-I receives input from the proteasome,
MHC-II from the endosome-lysosome system. However, this demarcation is not ab-
solute, and a proportion of endogenous antigens may be presented on MHC-II, and
exogenous on MHC-I, a phenomenon known as cross-presentation212. Autophagy
has been recognized as a mechanism for the entry of cytoplasmic and nuclear con-
tents into MHC-II loading compartments, with subsequent presentation to CD4+ T
cells200;213–216.
Constitutive autophagy in antigen-presenting cells leads to autophagosome in-
put to MHC-II loading compartments, and fusion of experimental antigens to LC3
leads to a marked increase in presentation on MHC-II200. Activation of autophagy
has effects on the MHC-II ‘ligandome’, leading to preferential presentation of intra-
cellular and nuclear antigens213;216. One functional consequence of increased MHC-
II cross presentation is enhanced immunity against intracellular microorganisms,
e.g. TB or HSV200;217. Autophagy may also post-translationally modify antigens –
citrullination of proteins has been noted to be promoted by peptidylarginine deim-
inase (PAD) activity in the autophagosome, which may lead to a source of novel
self-antigens, and autoimmune disease (as is seen in rheumatoid arthritis)218.
Interestingly, autophagy in thymic epithelial cells has been co-opted to display
self-antigen to developing T cells, and is therefore necessary for induction of anergy;




Autophagy is activated in monocytes following ex vivo stimulation with colony
stimulating factor-1 (CSF-1)219 or GM-CSF220, which induce differentiation into macrophages.
Inhibition of autophagy, either in vitro with the pharmacological autophagy in-
hibitor 3-MA, siRNA (short-interfering RNA), or in Atg7-/--Vav-Cre conditional knock-
out mice, restricts differentiation of human and murine monocytes. GM-CSF was
demonstrated to activate c-Jun N-terminal kinase (JNK) signaling, and to cause dis-
sociation of beclin-1 from Bcl-2220.
1.4.2 Autophagy and the adaptive immune system
1.4.2.1 Autophagy and T cells
Murine models deﬁcient in critical autophagy genes have demonstrated an impor-
tant role for this pathway during T cell development. Atg5-/-, Beclin-1-/- and Atg7-/--
Rag chimeras and Atg3F/F Lck-Cre, Atg5F/F-CD4-Cre, and Atg7F/F-CD4-Cre condi-
tional knockouts have decreased thymic cellularity, and with the exception of the
Atg3F/F Lck-Cre model, there is a proportional increase in frequency of cells at the
CD4-CD8- double negative (DN) stage221–224. Expression of autophagy genes is
maximal in DN thymocytes, as are levels of LC3-II222, and beclin-1225. This ob-
servation suggests that autophagy may be required for transition from this stage.
In the periphery, deﬁciency of Atg5, Atg7, and Atg3, but not Beclin-1, leads to
a signiﬁcant reduction in total T cell numbers, most pronounced in the CD8+ pop-
ulation. There is an increased proportion of T cells with the CD44hiCD62lo phe-
notype, which suggests homeostatic proliferation in response to lymphopenia226.
Autophagy is activated following T cell stimulation through the TCR, and further
enhanced by CD28 co-ligation225;227;228. Deﬁciency of Atg3 or Atg7 does not affect
stimulation-induced expression of the activation markers CD69 and CD25224;226, al-
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though a reduction in IL-2 production has been observed229. However, autophagy
is required for efﬁcient T cell proliferation222–224;229. Autophagy deﬁcient T cells
cultured in TH2 conditions are more susceptible to cell death during proliferation
than TH1 or TH17227;230.
A number of mechanisms are potentially responsible for this phenotype. Mito-
chondrial mass is increased in Atg5 and Atg7-deﬁcient T cells due to impaired mi-
tophagy, sensitizing them to apoptosis222;224;231, although mitochondrial accumula-
tion has not been observed in beclin-1 deﬁcient T cells. Autophagy is also required
for control of ER quantity (‘ERphagy’), and the resulting expansion of ER seen in
autophagy deﬁciency increases intracellular calcium stores, and impairs calcium in-
ﬂux in response to TCR cross-linking226. Whilst the defect in calcium ﬂux is marked,
it is probable that compensatory mechanisms exist, since calcium associated signal-
ing is relatively intact.
Autophagy may be required to provide for the metabolic needs of rapid cell di-
vision, as ATP levels are markedly depleted in stimulated Atg7-/- T cells, with some
restoration of cell viability upon addition of exogenous methylpyruvate229. Au-
tophagy may also promote T cell survival through degradation of proteins involved
in apoptosis, such as caspase-8230.
The potential importance of autophagy in the pathogenesis of autoimmune dis-
ease is illustrated by the observation that Beclin1F/F-CD4+-cre mice are completely
resistant to experimental allergic encephalitis (EAE) induced by myelin oligoden-
drocyte glycoprotein (MOG) immunization230.
1.4.2.2 Autophagy and B cells
In the bone marrow of an Atg5-/- Rag-/- chimeric mouse model, whilst there are nor-
mal numbers of pro- and pre-B-I cells, there is a substantial decrease in the propor-
tion of B cells at the pre-B-II and immature stages of development)232. A beclin-1-/-
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Rag-/- chimera displays similar abnormalities221. As described ??, the pro- and pre-
B stages are when Igh locus recombination occurs. However, whilst total periph-
eral B cell numbers are decreased in these models, in a similar Atg5-/- chimera223,
and in an Atg7F/F-Vav-Cre conditional knockout233, there are normal proportions of
transitional, follicular, and marginal zone B cells232. An Atg5F/F-CD19-Cre condi-
tional knockout has a subtler phenotype, with reductions only in mature B cells
(B220+CD43-IgM+IgD+) (2-fold) and peritoneal B1a cells (5-fold) with otherwise
normal peripheral B cell populations232.
Examination of a beclin-1-GFP reporter mouse demonstrates a biphasic pattern of
beclin-1 expression, with levels highest in pro-B cells, falling on transition to the pre-
B stage225. Interestingly however, beclin-1-GFP levels were also higher in mature
than transitional B cells. This pattern is similar to Bcl-2 expression234, and may
reﬂect the interaction between these proteins91. The dependency on autophagy for
B1a survival is interesting, as these innate-like cells have unique properties, such
as a long lifespan, the ability to self-renew, and constitutive production of ‘natural’
IgM235. They are also selected for self-reactivity, as natural IgM is important for
clearance of apoptotic cells and other debris236. It is possible that autophagy is
required for clearance of defective organelles or proteins that accumulate during the
lifetime of these cells, or that it is important in survival during the positive selection
events they undergo during their development.
TLR4 stimulation with LPS, or BCR ligation with anti-IgM induces autophagy in
cultured and primary murine B cells218;237;238, an effect attenuated by co-ligation of
CD40. The signaling events that lead to activation of autophagy are unknown.
Beclin-1-/- B cells appear to proliferate normally in response to LPS and IL-4 stim-
ulation221. However, this may not reﬂect a general phenotype of autophagy deﬁ-
ciency, as whilst beclin-1-/- T cells also proliferate normally, this is not the case for
Atg3-/-, Atg5-/-, or Atg7-/- T cells.
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Recently, autophagy has been demonstrated to be required for plasma cell devel-
opment238;239. In both reports, CD19-Cre-Atg5F/F conditional knockout mice were
studied. Autophagy was found to be activated following LPS stimulation of B cells
in vitro, with a peak in LC3 turnover and GFP-LC3 ﬂuorescence following 2 days
of stimulation, with a decrease to basal levels by day 4238. In vivo, following im-
munization with NP-Ficoll, there were more GFP-LC3 punctae in plasmablasts and
plasma cells than resting B cells. This is somewhat in opposition to the in vitSLEro
results, but may reﬂect differences in response to LPS compared with NP-Ficoll.
Pengo et al. also found enhanced ER stress and UPR activation, and unexpectedly,
increased antibody secretion from autophagy deﬁcient plasma cells, which were,
however, more prone to apoptosis than wild-type controls. They, as with Conway
et al., noted fewer bone marrow (BM) plasma cells in the CD19-Cre-Atg5F/F mice,
and an attenuated response to immunization with both T-dependent (TD) and in-
dependent (TI) antigens. Autophagy deﬁciency in B cells was determined to be
protective against experimental colitis. Neither group reported impairment of class
switching or GC formation.
Autophagy is also important in antigen processing in B cells. Autophagosomes
form constitutively in B cells200, and induction of autophagy in B cell lines by serum
starvation or in primary B cells by BCR ligation facilitates presentation of citrulli-
nated hen egg lysozyme (HEL) to cognate T cells, which does not occur if autophagy
is inhibited pharmacologically with 3-MA or by shRNA (short-hairpin RNA) anti-
sense to Atg5218.
Following BCR ligation, autophagy acts to recruit endosome localized-TLR9 to a
larger signaling compartment where hyperactivation of p38 MAPK occurs240. This
mechanism may account for the synergy observed with simultaneous BCR ligation
and TLR9 activation241 and is of potential signiﬁcance in the pathogenesis of SLE.
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1.5 Autophagy and its potential signiﬁcance in the
pathogenesis of SLE
1.5.1 Genetic association
GWAS of SLE have repeatedly highlighted variation at the Atg5-PRDM1 locus as
contributing towards disease risk. The Atg5-PRDM1 locus on chromosome 6 in-
cludes the genes Atg5, which as discussed above is a critical component of the
Atg5-Atg12-Atg16L1 complex, and PRDM1, which encodes Blimp-1, the master
transcription factor of plasma cell development. Both genes therefore, are relevant
candidates. The two genes are in linkage disequilibrium (LD), and whilst an ini-
tial study identiﬁed a risk SNP in an intron of ATG5, subsequent GWAS reﬁne the
association to the intergenic region, within a block of LD primarily encompassing
PRDM1. Two studies have attempted to clarify which of the two genes is affected
by the disease-associated variants. In the ﬁrst, CD4+ T cells and B cells were iso-
lated from Chinese controls and patients based on their genotype for rs6937876,
an intergenic SNP242. They found that in B cells, rs693SLE7876 was an expression
quantitative trait locus (eQTL) for Atg5 but not PRDM1 mRNA. There was no effect
in CD4+ T cells. A second study examined monocytes, and conventional and plas-
macytoid dendritic cells243. In this case, the intergenic risk SNP rs548234 reduced
expression of PRDM1. However, Atg5 expression was not quantiﬁed. The effects
of variation in the Atg5-PRDM1 locus are therefore complex and appear to be cell
type speciﬁc.
Other autophagy-associated genes that have shown disease association in SLE
GWAS include vesicle-associated membrane protein-7 (VAMP7), a protein involved
in homotypic fusion of autophagosomes244, and with a lesser degree of certainty
PIKFYVE, which encodes phosphoinositide 5-kinase245. A candidate gene-based
study in a Chinese population identiﬁed disease association with variants in Atg7
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and IRGM (immunity related GTPase M)242, the latter promoting autophagy through
as yet not fully deﬁned mechanisms246.
1.5.2 Existing experimental work
1.5.2.1 Autophagy in SLE
To date, autophagy in SLE has been examined in two studies. In the ﬁrst, Gros et
al. quantiﬁed autophagy using western blotting of LC3 and electron microscopic
imaging of autophagosomes in the MRLlpr/lpr and NZB/W F1 mouse models247.
They found activation of autophagy in thymocytes and peripheral T cells of disease
model mice, but were unable to detect a difference in unstimulated B cells. They also
found an increase in autophagy following stimulation of T cells with PMA and ion-
omycin, which was more pronounced in the NZB/W mice than controls. Intraperi-
toneal injection of LPS did, however, induce autophagy in the B cells of control mice.
They also examined peripheral T cells (CD4+ and CD8+) from patients with SLE us-
ing electron microscopy, and found an increased number of autophagosomes in the
disease patients compared with controls. Autophagic ﬂux was not assessed.
The second study looked at larger cohort of SLE patients, and divided T cells
by subset248. Using quantitative LC3 western blotting, they found no difference in
autophagy in the total T cell pool, but autophagy was enhanced in the naïve CD4+
population. B cells were not examined. They also found that treatment of healthy
donor CD4+ T cells with serum IgG from SLE patients induced autophagy, but that
SLE patient cells were resistant to this phenomenon.
1.5.2.2 Autophagy and other autoimmune diseases
The most fully characterized role for autophagy in autoimmunity is in the pathogen-
esis of Crohn’s disease. One of the major ﬁndings from GWAS in Crohn’s disease
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was an associated coding variant in Atg16L1 (T300A)249. Mice deﬁcient in Atg16L1
were demonstrated to have exaggerated macrophage production of IL-1β and IL-
18 following LPS stimulation, to be more susceptible to dextran-induced colitis, and
to have Paneth cell functional abnormalities207;250. In patients with the T300A risk
allele, corresponding Paneth cell granule abnormalities were also noted250.
Autophagy has also been implicated in rheumatoid arthritis, as a mediator of
TNF-α induced cartilage damage251. Autophagy is activated in osteoclasts from
mice with experimental arthritis, and joint damage is abrogated in TNF-α trans-
genic mice reconstituted with Atg7-/- bone marrow. Similarly, TNF-α treatment of
synovial ﬁbroblasts activates autophagy, and those cells from RA patients have in-
creased basal autophagy252. As described above, peptide citrullination may occur
as a consequence of autophagy in antigen presenting cells218. Anti-citrullinated
peptide antibodies are a hallmark of RA, and it is therefore possible that autophagy
may be a source of post-translationally modiﬁed novel auto-antigens that drive this
disease253.
In ankylosing spondylitis (AS), possession of the HLA-B27 allele is seen in the
great majority of patients (90%)254, but its role in disease pathogenesis is largely
unknown255. One hypothesis is that HLA-B27 misfolding occurs in the ER, lead-
ing to UPR activation and cytokine release256. However, it has been demonstrated
that in the gut of patient with AS, HLA-B27 misfolding leads to autophagy rather
than UPR activation, and that inhibition of autophagy with 3-MA in isolated lamina
propria cells reduces IL-23 secretion in response to LPS stimulation257.
1.5.3 Rationale for investigating autophagy in SLE
As has been outlined above, there is considerable overlap between the functions




















Figure 1.4: Hypothesized  role  of  autophagy  in  the  pathogenesis  of  SLE.  Au-
tophagy may lead to presentation of endogenous molecules on MHC-II,
modulate type I IFN production, and enhance the survival of autoreac-
tive immune cells. It may also inﬂuence the phagocytosis of apoptotic
cells, leading to their recognition as foreign.
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1 Introduction
Innate immune signaling Autophagy has key roles in both the detection of nu-
cleic acids, and also modulation of the subsequent response. Canonical autophagy
has been demonstrated to be required for TLR7 signaling in pDC204, and of par-
ticular note is that LAP is activated following Fc-γ receptor binding by immune
complexes, with subsequent TLR9 signaling206. SLE is a type I IFN mediated dis-
ease, and autophagy may contribute to the excessive production and dysregulation
of this key group of cytokines.
Survival of autoreactive cells SLE is characterised by a failure of immune tol-
erance mechanisms associated with the elimination of autoreactive immune cells.
Given the role autophagy is known to play in cell survival, it may be enlisted as a
mechanism to avoid homeostatic deletion of lymphocytes with self-reactive recep-
tors.
Recognition of self As outlined above (1.4.1.3), autophagy is important in the
presentation of endogenous molecules on MHC-II (cross presentation). This pro-
cess may enhance the repertoire and density of self-antigens displayed, with the
potential to incite autoimmunity.
1.5.4 Potential therapeutic considerations
Autophagy is modiﬁable by many existing pharmacologic agents, a signiﬁcant num-
ber of which are approved in the US and EU for other indications. Table 1.5.4 lists
some examples. One point of interest is that hydroxychloroquine, a standard med-
ication for SLE, inhibits autophagy by pH neutralization of the lysosome, which
therefore blocks autophagosome-lysosome fusion. Whilst it certainly has other modes
of action, e.g. inhibition of endosomal TLR signaling, autophagy inhibition may a








Table 1.2: Pharmacological modiﬁers of autophagy
without signiﬁcant off-target effects. For example, whilst the autophagy-activator
rapamycin is in clinical use as an immunosuppressant, mTOR inhibition has many





The following cell lines were used:
• GM12752 (EBV-transformed human lymphoblastoid cell line), (Coriell Insti-
tute for Medical Research, NJ, USA)
• Ramos RA-1 (human Burkitt’s cell lymphoma line, CRL1596), (American Tis-
sue Culture Collection, VA, USA)
Cells were passaged when a concentration of 1×106cells/ml was achieved.
2.1.2 Culture media and conditions
Cells were cultured in Roswell Park Memorial Institute-1640 media (RPMI-1640),
(Invitrogen, UK) supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine,
and 100U/ml penicillin/streptomycin (Invitrogen, UK), at 37°C and in 5% carbon
dioxide.
2.1.3 Human peripheral blood mononuclear cell preparation
Blood was collected into tubes containing 1:10 sterile acid-citrate-dextrose anticoag-
ulant (0.073g citric acid, 2.45g dextrose, 2.2g sodium citrate in 100ml water). Follow-
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ing 1:1 dilution with phosphate buffered saline (PBS), blood was layered onto ﬁcoll
(Histopaque HybriMax-1077, Sigma, UK), and density gradient centrifugation was
performed at 1600×g for 20 minutes at 21ºC. Platelets were removed by centrifuga-
tion at 200×g in PBS supplemented with 0.5% bovine serum albumin (BSA), (Sigma,
UK). Following separation, peripheral blood mononuclear cells (PBMC) were enu-
merated with a haemocytometer.
2.1.4 Murine splenocyte preparation
Spleens were mechanically dissociated by passage through a 70μm cell strainer (BD
Biosciences, UK). Erythrocytes were lysed using hypotonic buffer (RBC lysis buffer,
eBioscience, UK), and splenocytes were enumerated with a haemocytometer.
2.1.5 Magnetic cell separation
Human CD19+ B cells were separated using negative selection (Human Untouched
B Cell Kit, Invitrogen, UK). Brieﬂy, PBMC were incubated with biotinylated an-
tibodies against non-B cells, and then with streptavidin-conjugated magnetic mi-
crobeads. Magnetically labeled cells were subsequently separated in a magnetic
ﬁeld then discarded, and unlabeled B cells collected. Cell purity was checked using
ﬂow cytometry and found to be routinely >98%.
Murine B cells were also isolated using negative selection (Mouse Pan B Cell Kit,
Miltenyi, Germany), using a protocol similar to that described above. Cell purity
was routinely >98%.
2.1.6 Human cell stimulation
CD19+ B cells were cultured at a density of 3×105/well in a 48-well cluster plate
(BD Falcon, UK). For human plasmablast differentiation, B cells were stimulated
with ODN2006 (5μM) (Invivogen, San Diego, USA), IL-10 (50ng/ml) and IL-15
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(10ng/ml), (PeproTech, USA), and monoclonal mouse anti-CD40L (1μg/ml) (clone
82111, R&D Systems). Alternatively, human B cells were stimulated with goat anti-
IgM F(ab´)2 fragment (5μg/ml) (Stratech, USA) and monoclonal mouse anti-CD40L
(1μg/ml) (R&D Systems, USA).
2.1.7 Murine cell stimulation
Murine B cells were stimulated with lipopolysaccharide 10μg/ml (0111:B4) (Sigma,
UK) and IL-4 (10ng/ml) (PeproTech, USA).
2.1.8 Inhibition of autophagy
Autophagy was inhibited by 3-methyladenine (5mM), baﬁlomycin A1 (100nM), or
chloroquine (10μM), all from Sigma, UK.
2.2 Patients
Patients were recruited at sites of King’s Health Partners (St. Thomas’ and King’s
College Hospitals) following informed consent and with London Multi-centre Ethics
Committee approval (MREC 07/H0718/49). The mean age of the patients was 36,
with a male:female (M:F) ratio of 0.12. Patients were excluded if they had received
rituximab therapy within the last year, or intravenous methylprednisolone within
the preceding month. SELENA-SLEDAI scores were calculated258. Healthy con-
trols were recruited from King’s College London. The mean age of the controls
was 33 years, with a M:F ratio of 0.18. I found no statistical association between
age or sex and autophagy measures in the control group. Patient characteristics are




Female NZB/W F1 (NZB/W) and C57BL/6 (B6) mice were obtained from Charles
River, UK. Atg7Flox/Flox mice (a kind gift from Maasaki Komatsu, Tokyo Metropoli-
tan Institute of Medical Science, Japan) were crossed with Vav-iCre mice (a kind
gift from D. Kioussis, Medical Research Council National Institute for Medical Re-
search, London, UK) to obtain Vav-iCre; Atg7Flox/Flox. Male and female mice were
used equally, and Vav-iCre-; Atg7Flox/Flox and Vav-iCre+; Atg7Flox/WT littermates
were used as controls in comparative experiments. All mice were housed accord-
ing to local institutional care policies and under license.
2.4 Flow cytometry
Flow cytometry was performed on Canto II or Fortessa instruments (BD). In longi-
tudinal experiments, cytometer settings were standardized using Cytometer Setup
and Tracking Beads (BD Biosciences), run before each acquisition.
2.4.1 Viability and surface immunophenotyping
Cell viability was assessed by staining either using either 1μl/ml Live/Dead Green
(Invitrogen, UK), or Fixable Viability Dye 780 (eBioscience, UK), in 1ml PBS for 30
minutes at RT. Up to 1×106 cells were stained in 150μl buffer (PBS with 0.5% BSA). Fc
receptors were ﬁrst blocked for 10 minutes at 4°C with either Human Fc Receptor
Inhibitor (eBioscience, UK), or anti-mouse CD16/32 ([clone 9], eBioscience, UK).
Fluorochrome conjugated antibodies were then added, and the cells incubated for






















Table 2.2: Antibodies used in surface immunophenotyping of murine cells by
ﬂow cytometry
2.4.2 Annexin V staining
Annexin V staining was performed following surface staining, using recombinant
annexin V-phycoerythrin (eBioscience, UK), in calcium and magnesium containing
buffer (Annexin V staining buffer, [eBioscience, UK]), for 10 minutes at room tem-
perature.
2.4.3 Intracellular staining for p62
1×106 cells were Fc-blocked and surface stained as described in 2.4.1, then ﬁxed in








Phospho-p38 MAPK (Thr108/Tyr182) 36/p38
Phospho-Bcl-2 (Ser70) N46-467
Isotype Control Mouse IgG1￿ MOPC-21
Table 2.3: Antibodies used in phospho-epitope speciﬁc ﬂow cytometry (Phos-
Flow)
perature (RT). Cells were then washed in PBS, and then permeabilized and non-
speciﬁc binding blocked by incubation in the saponin-containing BD Perm/Wash
I (BD Biosciences, UK) for 15 minutes at RT. If secondary antibody staining was to
be performed, cells were also blocked in 10% normal goat serum (eBioscience, UK)
in Perm/Wash buffer for 30mins at RT.
Human cells were stained with mouse monoclonal anti-p62-Alexa Fluor 647 (1μg/ml)
(MBL, Japan) for 1 hour at room temperature, in Perm/Wash buffer I. Mouse cells
were incubated with monoclonal rabbit anti-p62 1:500 (clone D10E10, [Cell Signal-
ing Technology, USA]), washed twice in Perm/Wash buffer, and then with DyLight
649-goat anti-rabbit secondary antibody (Abcam, UK).
Isotype controls used for intracellular staining were monoclonal mouse IgG1κ
Alexa Fluor 647 (BioLegend) and monoclonal rabbit IgG XP® (clone DA1E, [Cell
Signaling Technology, USA]), for human and murine samples respectively.
2.4.4 PhosFlow staining
Cells were prepared and stained as described in section 2.4.1. Following overnight
storage at 4ºC in PBS, intracellular staining was performed. The anti-phospho-




Up to 1×106 cells were incubated in complete RPMI medium at 37°C for 30 minutes
in the presence of 0.25μl/ml Cyto-ID Green Autophagy Detection Reagent (Enzo,
UK). Cells were subsequently analyzed by ﬂow cytometry, with excitation using the
488nm laser. In some experiments, cells were ﬁxed with 4% paraformaldehyde (BD
CytoFix, BD Biosciences) for 15 minutes at room temperature following staining.
2.4.6 LysoID staining
Up to 1×106 cells were incubated in 500μL complete RPMI medium with 1μl/ml
LysoID Red (Enzo, UK), at 37°C for 30 minutes. The cells were washed once in
complete RPMI medium and then surface and intracellular staining was performed
as described in 2.4.1 and 2.5. Laser excitation for ﬂow cytometry was at 650nm.
2.4.7 MitoTracker staining
To prepare stock solutions of MitoTracker Green and Deep Red (both Invitrogen,
UK) vials of lyophilized dye were diluted with 74 and 92μL of dimethyl sulfoxide
(DMSO) respectively, to yield a 1mM concentration. For staining of cells, the stock
solutions were diluted to 100nM in complete RPMI medium. 1×105 cells were in-
cubated at 37°C in 500μl of the staining solution for 10 minutes, then washed twice
in PBS-BSA, before analysis by ﬂow cytometry, exciting MitoTracker Green using a
488nm laser, and MitoTracker Deep Red with a 650nm laser.
2.4.8 CFSE staining
A 5mM stock solution of carboxyﬂuorescein succinimidyl ester (CFSE) (eBioscience,
UK) was prepared in DMSO. 1×105 cells were washed twice in PBS (without BSA)
and stained with 500μL of a 10μM concentration solution of CFSE in PBS at room
62
2 Methods
temperature, in the dark, for 10 minutes. Labeling was then stopped by adding 3ml
of cold full RPMI media (at 4°C), with incubation on ice for 5 minutes. Cells were
then washed twice in PBS-BSA, and plated out for culture as appropriate.
2.5 Multispectral imaging ﬂow cytometry
Up to 5×106 cells were used per sample. Cells were stained for viability with Fix-
able Viability Dye (eBioscience, UK), and then Fc receptors were blocked (mouse:
anti-CD16/CD32 [clone 9]; human: Fc Receptor Binding Inhibitor, both from eBio-
science, UK). Cells were surface stained using antibodies listed in tables 2.4.1 and
2.4.1, then ﬁxed and permeabilized with the BD Fix/Perm kit I (BD Biosciences). For
mouse cells, samples were blocked with 10% goat serum and then incubated with
rabbit polyclonal anti-LC3 (Novus Bio, USA) diluted 1:400 in Perm/Wash I for 1
hour at 4°C, washed, and then with Alexa Fluor 488-goat anti-rabbit secondary an-
tibody 1:500 (Invitrogen, UK).
For human cells, samples were incubated with mouse monoclonal anti-LC3-ﬂuorescein
isothiocyanate (FITC) 1:400 (Enzo Life Sciences, clone 2E6) and mouse monoclonal
anti-active capase-3-PE (BD, clone C92-605) for 1 hour at 4°C, then washed twice.
In all cases, cells were resuspended in 100μl PBS for analysis.
MIFC was performed on an Amnis ImageStreamX instrument.
Up to 1×105 images were acquired per sample. The 488nM laser was used at
120mW. Using the Bright Field channel, cells were gated on aspect ratio to include
only singlets, and then the gradient root-mean-square feature to include focused
cells. The cell surface was excluded using a mask (deﬁnition: erode 3) based on the
bright ﬁeld image. Alternatively, the Bright Detail Intensity (BDI) R3 algorithm was
applied to the FITC channel.
For determination of LC3+ punctae numbers, the Spot Count algorithm was used
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following application of a Spot isolation mask (deﬁnition: bright, spot:background
ratio 3, size 3).
For co-localization of organelles, following staining with LysoID (2.4.6) and anti-
LC3 as described above, the Bright Detail Similarity (BDS) algorithm was applied.
The BDS algorithm uses the log transformed Pearson’s correlation co-efﬁcient of
bright details 3 pixels or less included in the masked area, from two input images.
All image analysis was using the Amnis IDEAS 6.0 software package.
2.6 Confocal microscopy
1×106 Ramos cells were stained with 0.25 μl/ml Cyto-ID Green Autophagy Detec-
tion Reagent and 1 μl/ml Lyso-ID Red in 1× Assay buffer at 37°C for 15 minutes.
Cells were mounted in SlowFade reagent (Invitrogen, UK). Microscopy was per-
formed on a Nikon A1R Confocal microscope.
2.7 Protein analysis
2.7.1 Cell lysis
Cells were lysed in ice-cold radioimmunoprecipitation (RIPA) buffer (150 mM NaCl,
1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0
[Sigma, UK]), supplemented with protease and phosphatase inhibitors (Complete
Mini and PhoSTOP, Roche, UK) for 15 minutes, then clariﬁed by centrifugation at
10000×g for 10 minutes
2.7.2 Protein quantiﬁcation
To quantify protein concentration, the colorimetric bicinchoninic acid (BCA) assay
was used (Thermo Scientiﬁc, UK). The BCA method quantiﬁes reduction of copper
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to the cuprous cation (Cu+) by protein. A ratio of analyte to working reagent of 1:8
was used in a 96-well ﬂat-bottomed microplate. Protein concentration was quan-
tiﬁed by running an albumin standard curve. The plate was incubated at 37°C for
30 minutes, and read in a spectrophotometer at 495nm. Samples were assayed in
triplicate, and the mean determined.
2.7.3 Immunoblotting
Twenty-ﬁve μg protein per well were heated in sample buffer (2% SDS, 50mM Tris
pH 6.8, 10% glycerol, 10% mercaptoethanol) at 95°C for 5 minutes, then loaded into
3-15% Tris-Glycine gels (BioRad, UK). Recombinant Rainbow Marker (GE Amer-
sham, UK) was used to determine protein size. Electrophoresis was performed in
running buffer (25mM Tris, 250mM glycine pH 8.3, 0.1% SDS) until sufﬁcient sepa-
ration of protein bands was achieved. The gel was allowed to equilibrate in transfer
buffer for 20 minutes (20% methanol, 25mM Tris, 250mM glycine). The protein con-
tents of the gel were transferred onto PVDF (polyvinylidene ﬂuoride [Immobilon
P, Merck Millipore, UK]) membranes by wet electroblotting in transfer buffer. Fol-
lowing transfer, the membrane was brieﬂy washed in methanol and allowed to air
dry for 30 minutes before further use.
Membranes were blocked with 5% non-fat milk in Tris buffered saline (150mM
NaCl, 50mM Tris) with 0.05% Tween-20 (TBS-T) or 2.5% BSA in TBS-T (for phospho-
epitope immunodetection) for 1 hour at room temperature then probed overnight
with either polyclonal rabbit anti-p62 1:40000 (MBL, Japan), rabbit polyclonal anti-
LC3 1:4000 (Novus, UK), rabbit monoclonal anti-phospho-mTOR [Ser2448] 1:4000,
anti-mTOR 1:4000, anti-phospho-4EBP1 [Thr37/46] 1:10000, or anti-β-actin 1:20000
(Cell Signaling Technology), all in blocking buffer. Membranes were then washed
for 10 minutes × 3 in TBS-T, and then incubated with 1:40000 HRP-conjugated goat




Blots were developed with Luminata Forte ECL (Merck Millipore, UK), and Fuji
radiographic ﬁlms.
2.7.4 ELISA
2.7.4.1 Murine immunoglobulin isotyping
Murine immunoglobulin subclasses were determined using the semi-quantitative
Mouse Ig Isotyping Ready-Set-Go kit (eBioscience, UK). This assay detects IgM,
IgA, IgG1, IgG2a, IgG2b, IgG3, and κ/λ chains. The assay was prepared by coat-
ing wells of a 96-well ﬂat bottomed ELISA plate (Nunc, Denmark) with capture
antibody diluted in 100μl per well of PBS, and incubating overnight at 4°C. Each
well was washed twice with 400μl wash buffer (PBS with 0.05% Tween-20), and
then blocked with 250μl blocking buffer (PBS with 1% Tween-20 and 10% BSA) for
2 hours at RT. The wells were washed twice with 400μl wash buffer, and 50μl per
well of assay buffer (PBS with 1% Tween-20 and 10% BSA) was added. Fifty-μl of
tissue culture supernatant was then added and the plate incubated for 1 hour at RT
on a plate shaker. Wells were washed 4 times with 400μl wash buffer, and then
100μl detection antibody was added. The plate was again incubated for 1 hour at
RT on a plate shaker, and then washed four times with 400μl wash buffer. One
hundred-μl per well of tetramethylbenzidine (TMB) substrate was then added, and
the plate incubated at RT for 15 minutes. Following substrate development, 100μl
stop solution (2N H2SO4) was added, and the plate read at 450nm.
2.7.4.2 Phospho-AMPK
AMPK phosphorylated at Thr172 in B cell lysates was quantiﬁed using the Invit-
rogen AMPK [T172] ELISA kit (Invitrogen, UK). Cells were lysed as described in
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2.7.1. Twenty-ﬁve μg protein made up to 100μl with diluent buffer was used per
well of pre-coated strips. Samples were incubated for 2 hours at RT, then washed 4
times with 400μl wash buffer. Anti-AMPK (Thr172) antibody was then added, and
the plate incubated for 1 hour at RT, followed by washing 4 times with 400μl wash
buffer. The wells were incubated with anti-rabbit horseradish peroxidase (HRP) de-
tection antibody for 30 minutes at RT, then washed 4 times with 400μl wash buffer.
Stabilised chromogen was then added, and the plate incubated in the dark at RT
for 30 minutes. One-hundred μl stop solution was added, and the plate read at
450nm. pAMPK concentration was determined using a standard curve calculated
with pAMPK standards.
2.7.5 Luminex
Phosphorylated and total proteins were measured using antibody-capture ﬂuores-
cent microspheres in a suspension array system. This methodology uses micro-
spheres (beads) with individual ﬂuorescent identity labels (addresses) that allows
the assay to be multiplexed. The microspheres are conjugated to a capture antibody,
and following binding of the target antigen, a secondary biotinylated detection an-
tibody is used, and after the addition of streptavidin-phycoerythrin (SA-PE), the
assay is read by a 96-well microplate format ﬂow cytometer.
B cells were isolated and lysed as described in sections 2.1.5 and 2.7.1. Following
quantiﬁcation, 5μg of protein was assayed per well of a 96-well microplate. The
following antibodies were used (all Bio-Rad BioPlex, UK):
The following control proteins were used (all Bio-Rad, UK):
The samples were mixed with the multiplexed coupled beads diluted in 50μl
wash buffer per well, and incubated overnight at room temperature at 300rpm on
a plate shaker, in the dark. The beads were then washed 3 times in 200μl of wash




Phospho-GSK3-alpha/beta (Ser9/21) Total GSK3
Phospho-Akt (Thr308) Total Akt
Phospho-ERK1/2 (Thr202/Tyr204, Thr185/Tyr187) Total ERK1/2
Phospho-p70-S6K (Thr421/Ser424) Total p70-S6K
Phospho-p38 MAPK (Thr180/Tyr182) Total p38 MAPK
Table 2.4: Antibodies used in suspension array system (Luminex)
Control protein Pathway
Epidermal growth factor (EGF)-treated HEK293 cell lysate Akt, GSK3, ERK1/2
Nerve growth factor-beta (NGF-beta)-treated PC12 cell lysate p70-S6K
Phosphatase-treated HeLa Negative control
Table 2.5: Control proteins used in suspension array system (Luminex)
its diluent was added to each well. The samples were then incubated at room tem-
perature for 30min on a plate shaker at 300rpm. The plate was washed three times
with 200μl wash buffer, and then 50μl of streptavidin-PE was added to each sam-
ple. The samples were incubated at room temperature for 10min on a plate shaker
at 300rpm. The samples were washed three times with 200μl wash buffer, and then
resuspended in 125μl resuspension buffer. Analysis was performed on a Luminex
FlexMap 3D instrument (Luminex, US). Each sample was analyzed in duplicate.
2.8 Statistical analysis
Data were analyzed using GraphPad Prism 5.0 (GraphPad Software, US), or R 2.11
(The R Foundation for Statistical Computing, US). Data were tested for normality
using the D’Agostino and Pearson omnibus normality test. The selected statistical
test is shown in each ﬁgure legend.
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cytometry
3.1 Introduction
Measurement of autophagy has been an area of intense interest over recent years,
and has also generated controversy; consensus based guidelines endorsed by lead-
ers in the ﬁeld have emerged21;259;260, but their length and breadth reﬂect the fact
that no single methodology is universally applicable.
Most techniques detect autophagosome-associated LC3, either by immunoblot-
ting, based the electrophoretic mobility shift seen when it is conjugated to PE (LC3-
II), or by imaging autophagosomes, deﬁned as LC3+ punctae, through immunohis-
tochemistry or following LC3-GFP transfection.
However, immunoblotting and conventional microscopy have the disadvantage
that they are low-throughput, and cell population subset analysis is challenging.
Furthermore, in a cross-sectional study, semi-quantitative immunoblotting typi-
cally yields high inter-experimental variability, and with microscopy it may be dif-
ﬁcult to achieve statistical power with comparatively small sample sizes.
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3.1.1 Multispectral imaging ﬂow cytometry
The development of multispectral imaging ﬂow cytometry (MIFC), which allows
high-throughput imaging of single cells in ﬂow, provides a potentially useful plat-
form for quantifying autophagy and has already been utilized and evaluated for this
purpose261–263. Cells of interest can be identiﬁed by conventional immunopheno-
typing based on ﬂuorochrome-conjugated antibodies. For a longitudinal study of ex
vivo immune cells, MIFC has notable advantages compared with e.g. immunoblot-
ting, in that machine parameters can be standardized and maintained over time,
and also dead or apoptotic cells, which may potentially be confounding, can be ex-
cluded from analysis by standard assays.
3.1.2 CytoID autophagosomotropic dye
Whilst dyes have been used previously to stain autophagosomes (e.g. acridine or-
ange, LysoTracker Red, or monodansylcadaverine)21, they have the major disad-
vantage that there is signiﬁcant off-target staining of lysosomes, and high non-
speciﬁc background staining264. Recently, a novel proprietary amphiphilic tracer
dye, CytoID, has been introduced. Uptake of this dye has been shown to have good
correlation with LC3-II levels, and there have been reports of negligible lysosomal
staining265–267. CytoID may therefore provide a complementary methodology for
assessing autophagy by ﬂow cytometry.
3.2 Aims
In this chapter, I evaluate and conﬁrm the utility of MIFC and CytoID for the quan-
tiﬁcation of autophagy.
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3.3 Results
3.3.1 MIFC provides a functional, high-throughput means for
quantifying autophagy
An Epstein-Barr virus transformed human B lymphoblastoid cell line (LCL) was
selected for initial experiments. Following ﬁxation and permeabilization, the cells
were stained with monoclonal FITC-conjugated anti-LC3 antibody and data were
acquired on an Amnis ImagestreamX instrument. As a positive control, cells were
treated with the H+ ATPase pump inhibitor baﬁlomycin A1 for 18 hours to inhibit
autophagy by blocking autophagosome-lysosome fusion, but thereby increase the
number of LC3+ autophagosomes. To inhibit autophagy, the class III PI3K inhibitor
3-MA was used.
Figures 3.1 and 3.2 show the gating strategy, and example images from this ex-
periment. Two algorithms were evaluated: the Spot Count mask and the Bright
Detail Intensity algorithm, both implemented within the platform speciﬁc applica-
tion IDEAS 6.0.
Analysis was performed by selecting focused images of single cells, applying a
mask to exclude the cell surface, and then, in the case of the Spot Count algorithm,
using a further mask to deﬁne and count spots, based on size and threshold. Alter-
natively, the Bright Detail Intensity algorithm was used, which rather than using a
user-deﬁned mask to quantify spots, automatically subtracts the background signal
from ‘bright details’ 3 pixels or less in diameter, and then quantiﬁes their intensity.
The ﬁnal value from the BDI algorithm is the integrated sum of the brightness of all
the isolated details in the mask area. Representative distributions from the BDI and
Spot Count algorithms are illustrated in ﬁgure 3.1. Staining of cells with a FITC-
conjugated isotype control antibody is shown in ﬁgure 3.3.
The distribution of BDI has a degree of left-skew, and therefore an empirical gate
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Figure 3.1: Example MIFC gating and distributions. A. Clumped cells were ex-
cluded from analysis by gating on aspect ratio and area. B. Focused
cells were included based on the gradient root-mean-square feature of
the bright ﬁeld images. C & D. Example distributions of the BDI and
Spot Count features following treatment of lymphoblastoid cells for 18
hours with 100nM baﬁlomycin A1 or 5μM 3-methyladenine. Experiment
performed twice with equivalent results.
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Figure 3.2: Example MIFC images. A. Representative images of lymphoblastoid
cells from high and low quantiles of LC3-FITC Spot Count. B. Effect of
in vitro pharmacologic increase (with baﬁlomycin 100nM) or decrease
(with 3-methyladenine 5μM) of autophagosomes on Spot CountHI pop-
ulation following 18 hours of culture. C&D. Equivalent data for Bright
Detail IntensityHI population. n=3 per group, 1×104 cells per sample.
Images are merged Bright Field and FITC (LC3) channels. Experiment
performed twice with equivalent results.
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Figure 3.3: Isotype control staining and distribution. LCLs were stained with iso-
type control or FITC conjugated anti-LC3 antibody then analysed using
the spot count algorithm. Example distributions (A) and images (B) are
shown.
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was placed on a reference control population histogram to include the highest 10%
of BDI, which was classiﬁed as BDIHI. The Spot Count distribution is bimodal, with
a signiﬁcant number of cells classiﬁed as having zero spots, with a secondary left-
skewed distribution. Again, a gate was set empirically based on a reference control
population to deﬁne Spot CountHI cells.
Both analytic modalities discriminated between LCLs treated with baﬁlomycin
or 3-MA compared with untreated control cells.
3.3.2 CytoID has minimal off-target lysosomal staining and is suitable
for ﬂow cytometry
Next, to evaluate an alternative method of high-throughput quantiﬁcation of au-
tophagy, which, as with MIFC shares the inherent advantages of analysis by FACS,
I performed experiments to determine the performance of CytoID dye.
Firstly, to conﬁrm staining distinct from the lysosomal compartment – a disadvan-
tage of alternative dyes, I performed confocal microscopy of cells from the Ramos
B cell line co-stained with CytoID, and LysoID, a speciﬁc and well established lyso-
some tracer dye (ﬁgure 3.4). There was good distinction between autophagosomes
and lysosomes. I next performed ﬂow cytometry of LCLs treated with the mTOR
inhibitor rapamycin for 18 hours to induce autophagy. There was a higher CytoID
MFI in the rapamycin treated cells than in untreated control cells (ﬁgure (3.4)).
There was a moderate but statistically signiﬁcant correlation between CytoID MFI
and forward scatter (FSC) (r=0.4, p<0.0001), a laser deﬂection pattern in most cir-
cumstances proportional to cell size.
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Figure 3.4: Evaluation of CytoID dye. A. Confocal microscope image of Ramos B
cell line stained with LysoID (lysosomotropic) and CytoID (autophago-
somotropic)  dyes. B.  Correlation between Forward Scatter  and Cy-
toID MFI in human PBMC. C. Example histograms of CytoID MFI from
control and rapamycin treated LCLs (200nM rapamycin or control for
18 hours). D. CytoID MFI/FSC ratio in LCLs treated with 200nM ra-
pamycin or control for 18 hours. n=3 wells per condition.
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3.4 Discussion
In this chapter, I have conﬁrmed that MIFC and CytoID represent practical modali-
ties for the quantiﬁcation of autophagy in further experiments. The utility of MIFC
is due to the combination of easy collection of image data from large numbers of
individual cells, providing statistical power, with the functional advantages of ﬂow
cytometry e.g. multiplex parameter measurement. Furthermore, the Amnis ImagestreamX
instrument incorporates quality control routines that conﬁrm instrument stability
between experiments, making it suited to clinical longitudinal studies. Of the two
algorithms assessed for further use, both discriminated well between cells in which
autophagy had been induced or inhibited. I elected to use the Spot Count algo-
rithm for further cell analysis, as it reproduced the widely used and reported LC3+
punctum count.
CytoID dye demonstrated limited co-staining with LysoID by confocal microscopy,
in keeping with manufacturer data and other reports in the literature265–267. Treat-
ment with the autophagy activator rapamycin increased CytoID staining in LCLs,
as would be expected. A signiﬁcant question in the interpretation of CytoID ﬂuo-
rescence is the effect of cell size on non-speciﬁc signal. There was a moderate but
highly statistically signiﬁcant correlation between CytoID MFI and FSC (r=0.4). It is
somewhat unclear to what extent this relationship can be considered as relevant to
the choice of the optimum metric for the dye. However, as there may be signiﬁcant
differences in cell size within e.g. B cell subsets, the ratio between CytoID MFI and
FSC has been chosen as the reported outcome variable.
CytoID is a particularly convenient method for quantiﬁcation of autophagy, as
staining is rapid and since total ﬂuorescence is the measured parameter, it can be
used with conventional FACS, which may allow a wider range of ﬂuorochromes to
be incorporated in the experimental design.
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4.1 Introduction
Whilst there have been studies exploring autophagy in SLE247;248, they have only
examined T cells in human disease. The results have been somewhat conﬂicting;
one group noting activation of autophagy only in naïve CD4+ and CD8+ T cells,
but not the whole T cell pool248, whilst another found up-regulation in all CD4+ T
cells247. B cells, a major driver of the pathogenesis of SLE, and monocytes, have
not been studied. In this chapter, I use the MIFC and autophagosomotropic dye
assays described in chapter 4 to study ex vivo cells of patients with SLE, with focused
attention on the B cell pool. I then explore the effects of varying stimulation on
autophagy on human cells in vitro, and ﬁnally, attempt to determine the mechanism
of autophagy activation in SLE.
4.2 Aims
In this series of experiments, I seek to determine if there is a difference in autophagy
in B cells, CD4+ T cells, and monocytes in patients with SLE compared to healthy
controls, and to explore the potential mechanisms for my ﬁndings.
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4.3 Results
4.3.1 Autophagy is increased in SLE patient B and CD4+ T cells
compared with healthy controls
In the MIFC experiment, PBMCs from cases and controls were isolated and then
stained for surface phenotype markers (CD19, CD4, and CD14), viability, and with
anti-LC3 and active caspase-3 antibodies following permeabilization. An increase
in apoptotic lymphocytes is observed in SLE268, and so one further advantage of
MIFC is that using anti-active caspase-3 antibody, apoptotic cells may be removed
from the analysis, removing a potentially confounding variable.
To explore clinical parameters, and in particular to attempt to determine the ex-
istence of confounding due to immunosuppressive medication, disease activity (as
measured by the SELENA-SLEDAI), C3/4, autoantibody status, and medication
were recorded.
Figures 4.1 and 4.2 demonstrate the gating strategies used, example distributions,
and images of CD4+ T cells, CD19+ B cells, and CD14+ monocytes.
There were signiﬁcantly more CD19+ B cells and CD4+ T cells with high num-
bers of autophagosomes (LC3+ punctae) in the SLE patients compared with healthy
controls. There was no difference however, in the CD14+ monocytes (ﬁgure 4.3).
Differential autophagy in B cells is a novel ﬁnding, and I therefore focused further
experimental work on investigation of this observation.
The inﬂuence of clinical parameters on B cell autophagosome count was deter-
mined by univariate linear regression (table 4.3.1). First, correlation between SLEDAI
score and autophagosome count was sought; there was a modest but signiﬁcant as-
sociation between these two parameters (r2 0.2, p=0.03) (Table 4.3.1, Figure 4.4).
Immunosuppressant medication, in particular corticosteroids and hydroxychloro-
quine, has the potential to modulate autophagy and therefore confound the re-
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Figure 4.1: Example MIFC gating strategy for B cells. MIFC images of isolated
human PBMCs were ﬁrst acquired. Doublets and cell debris were ex-
cluded by gating on cell brightﬁeld area and aspect ratio. Next, focused
cells were selected by gating on cells exceeding a brightﬁeld root-mean-
square threshold. Viable cells were gated on the exclusion of a ﬁxable
viability dye, and then CD19+, active caspase-3 low gates selected non-
apoptotic B cells.
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Figure 4.2: Example images of CD19+ B cells, CD4+ T cells, and CD14+ monocytes
with high and low Spot Counts. PBMCs were surface stained, then
intracellular staining with LC3-FITC was performed. Following image
acquisition and preliminary analysis as outlined in ﬁgure 4.1, the Spot
Count algorithm was applied. High and low quantiles of Spot Count are
shown.
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Figure 4.3: Autophagosome density is increased in CD19+ and CD4+ T cells but
not CD14+ monocytes in SLE. Each point represents one individual pa-
tient or control. The Spot Count (LC3+ punctae) in A. CD19+ B cells, B.
CD4+ T cells, C. CD14+ monocytes as determined by MIFC is depicted.
Student’s unpaired t test used for comparisons.
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Covariate Beta-coefﬁcient Std Error t value r2 p
SLEDAI score 1.95 0.85 2.30 0.20 0.03
Anti-dsDNA (0/1) -0.26 5.04 -0.052 - 0.96
Anti-Ro (0/1) 6.27 4.749 1.32 - 0.2
Low C3/4 (0/1) -0.90 4.90 -0.184 - 0.2
Anti-RNP/Sm (0/1) -1.31 5.30 0.248 - 0.8
Table 4.1: Univariate linear regression modeling of SLEDAI and laboratory pa-
rameters on B cell LC3+ Spot Count
Covariate Beta-coefﬁcient Std Error t value r2 p
Hydroxychloroquine (mg) -0.008 0.014 -0.519 - 0.61
Prednisolone (mg) 0.2 0.3761 0.543 - 0.66
Azathioprine (mg) 0.018 0.047 0.424 - 068
Mycophenolate mofetil (mg) -0.001 0.0034 -0.47 - 0.64
Table 4.2: Univariate linear regression modeling of the effect of medication on
B cell LC3+ Spot Count
sults269;270. However, there was no statistically signiﬁcant correlation between med-
ication and autophagy in the sample. There was also no association between anti-
Ro, anti-RNP and anti-dsDNA antibodies, or low C3/4 and autophagy. However,
these results should be interpreted with some caution, as the small sample size for
regression analysis makes type II error likely. There were insufﬁcient sample num-
bers for multivariate regression.
4.3.1.1 Autophagic ﬂux is increased in SLE B cells
Standard techniques that quantify LC3-II, either by its electrophoretic mobility fol-
lowing SDS-PAGE and immunoblotting, or by visualization of autophagosomes,
have the inherent limitation that they cannot quantify autophagic ﬂux. Therefore,
it has become accepted practice that cells are examined with and without an in-
hibitor of autophagosome degradation, typically one that prevents fusion with the
lysosome, such as chloroquine or baﬁlomycin A1, or inhibits lysosomal proteases,
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Figure 4.4: A. Correlation between SLEDAI and B cell autophagy. B. Autophagic
ﬂux assay. Isolated CD19+ B cells from patients with SLE were incu-
bated in complete RPMI media with 20μM chloroquine for 4 hours, and
then LC3+ Spot Count determined using MIFC. Pearson’s correlation co-
efﬁcient used in A. Paired student’s t test used in B.
e.g. pepstatin/leupeptin. Accumulation of autophagosomes or LC3-II with the ad-
dition of the clearance inhibitor indicates active ﬂux, whereas no increase suggests
a clearance defect.
To examine autophagic ﬂux in SLE B cells, CD19+ cells were isolated, and incu-
bated in complete RPMI with and without 20μM chloroquine for 2 hours (ﬁgure
4.4). Active ﬂux was conﬁrmed by an increase in the LC3+ Spot Count following
this period.
An alternative technique to infer active autophagic ﬂux is to directly observe
fusion of autophagosomes with lysosomes by microscopy. Co-localization of au-
tophagosome (typically LC3) and lysosomal markers (e.g. lysosomal-associated
membrane protein-1 [LAMP-1], or a lysosomotropic dye) is taken to represent ﬂux,
whereas lack of spatial association implies a defect in terminal fusion. Recently,
it has been demonstrated that MIFC may be used to measure this co-localization
in a high-throughput manner263, and I therefore utilized this established protocol
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to examine autophagic ﬂux in the B cells of a group of SLE patients and healthy
controls.
To quantify co-localization, the Bright Detail Similarity algorithm implemented
in Amnis IDEAS 6.0 was used. The BDS algorithm computes the log-transformed
Pearson’s correlation co-efﬁcient between ‘bright details’ 3 pixels or less in diam-
eter from two image channels. To identify autophagosomes, LC3-FITC intracellu-
lar staining was used as described above. Lysosomes were marked with the lyso-
somotropic dye LysoID. Examples of B cells with low and high levels of BDS are
shown in ﬁgure 4.5. I found no impairment of lysosome-autophagosome fusion in
SLE compared with healthy controls in a limited sample size.
4.3.1.2 B cell subset analysis with CytoID
To conﬁrm the observations made using MIFC, I employed CytoID staining to quan-
tify autophagosome density in B cell subsets. In accordance with the results seen
using MIFC, there was higher CytoID ﬂuorescence in the SLE patient B cells than
the healthy controls. B cells subsets were deﬁned as naïve (CD27+, IgD+), mem-
ory (CD27+, IgD-), and plasmablast (CD27++, IgD-), based on their expression of
the TNF-superfamily receptor CD27, and IgD. I found that autophagosome den-
sity was differentially higher in the naïve subset, compared with the memory and
plasmablast subsets in patients with SLE compared with healthy controls (ﬁgure
4.6).
4.3.1.3 p62 levels are lower in naïve and memory B cell subsets in SLE
An alternative method for quantifying autophagic ﬂux is to measure the levels of
autophagy substrate proteins, whose level decreases with increased autophagic ac-
tivity. One typically used such protein is p62, which serves as an autophagosome
adapter protein, and which is degraded primarily by autophagy. In order to allow
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Figure 4.5: Active autophagosome-lysosome fusion in SLE. Examples of CD19+ B
cells with high and low levels of spatial correlation between LC3 (green)
and lysosomes (red). Mann-Whitney U test used.
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Figure 4.6: Analysis of autophagy in B cells with CytoID. A. Gating strategy for
naive (CD19+CD27-IgD+), memory (CD19+CD27+IgD-) and plasmablast
(CD19+CD27++IgD-) B cells. B. CytoID uptake is signiﬁcantly increased
in SLE vs. healthy controls. C. Differential autophagy between SLE and
controls is maximal in the naive subset. B. Mann-Whitney U test used.
C. ANOVA, *p<0.05
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convenient longitudinal data collection in B cell subsets, I employed intracellular
FACS using a monoclonal, ﬂuorochrome conjugated anti-p62 antibody (ﬁgure 4.7).
These results mirrored those seen in the CytoID experiment; decreased p62 levels
in the naïve and memory B cell subsets in SLE compared with healthy controls (ﬁg-
ure 4.8). Notably, whilst p62 levels were lower in B cells, there was no signiﬁcant
difference in CD4+ T cells.
This experiment, in conjunction with the ﬂux inhibitor results described above, is
highly indicative of intact autophagic ﬂux in SLE B cells.
4.3.2 Autophagy is downregulated in B cells in vitro as stimulatory
support is increased
The results presented above indicate that autophagy is activated in SLE, but the
relevance of this ﬁnding is not clear. It may represent either cell stimulation, or be a
means to resist cell death. To start to elucidate this question, I cultured ex vivo B cells
from healthy donors with additive combinations of stimuli, and assessed activation
of autophagy using CytoID uptake.
I found that autophagy substantially increased following 24 hours of culture com-
pared with baseline, but that the activation of autophagy was abrogated in an addi-
tive fashion with anti-IgM, anti-CD40, and interferon-α treatment (ﬁgure 4.9). This
observation mirrors an increase in apoptosis enumerated by annexin V binding,
which is suppressed by anti-IgM treatment (ﬁgure 4.10).
Interestingly, on a single cell level, there appeared to be a degree of mutual ex-
clusivity between autophagy and apoptosis, with autophagy much diminished in
annexin V+ cells. This may be expected given their reciprocal relationship, medi-
ated at least in part by the interaction between Bcl-2 and beclin-191. The association
between activation of autophagy and cell death is highlighted by a strong inverse
correlation between the extent of CytoID uptake and cell viability, assessed by the
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Figure 4.7: p62 levels in SLE and healthy control lymphocytes. A. Example distri-
butions of p62 MFI in SLE and controls. B&C. p62 MFI is lower in CD19+
B cells from patients with SLE compared with controls, but not in CD4+
T cells. B. Unpaired t test used, C. Mann-Whitney U test used.
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Figure 4.8: p62 levels in B cell subsets. p62 levels are lowest in the naïve B cell
subset, followed by memory B cells. There was no statistically signif-
icant difference observed in plasmablasts. Pairwise comparisons be-
tween SLE and controls made by preplanned, unpaired t test. Unad-
justed p value shown.
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Figure 4.9: Autophagy in vitro following B cell stimulation. A. Human B cells
were isolated and stimulated with combinations of anti-IgM, anti-CD40,
and interferon-α for up to 48 hours, then viability determined by ex-
clusion of ﬁxable viability dye. B. CytoID staining for the experiment
described in A. C. Correlation between cell viability and CytoID uptake
after 24 hours of culture. n=3 per treatment condition, representative
experiment shown, repeated in triplicate. C. Pearson’s correlation used.
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Figure 4.10: In  vitro relationship  between  autophagy, apoptosis, and  cell  ac-
tivation  in  B cells. A.  Apoptosis  was  determined  by  annexin  V-
phycoerythrin staining in B cells stimulated with anti-IgM for 24 hours.
B. Co-staining with CytoID and annexin V-phycoerythrin. C. CytoID
uptake in CD86 low or high cells. n=3 per treatment condition, rep-
resentative experiment shown, repeated in triplicate, except C, which
includes data from multiple wells in 3 separate experiments. B. Pre-
planned unpaired t test used for pairwise comparisons; C. unpaired t
test used.
92
4 Assessment of autophagy in human SLE
exclusion of a vital dye (ﬁgure 4.9). A potentially analogous result is that CytoID
uptake was signiﬁcantly increased in B cells with high levels of the co-stimulatory
molecule CD86. CD86 is up-regulated in antigen presenting cells following their ac-
tivation, and this ﬁnding suggests that autophagy is reduced in cells that are likely
to have received sufﬁcient survival signaling to avoid cell death.
4.3.2.1 mTOR is activated following B cell stimulation
Using the stimulation and culture conditions described in the preceding experi-
ment, I examined the phosphorylation status of mTOR (at Ser2448) and 4E-BP1
(Thr37/46) in ex vivo B cells from healthy donors, using immunoblotting. Phos-
phorylation of mTOR at Ser2448 by S6K leads to mTOR activation271. 4E-BP1 phos-
phorylation by mTORC1 releases it from the mRNA cap binding protein eukaryotic
initiation factor-4E (eIF4E), allowing initiation of protein translation272. I found that
mTOR and 4E-BP1 were increasingly phosphorylated with anti-IgM and anti-CD40
stimulation, following culture for 24 hours (ﬁgure 4.11). Untreated cells had the
lowest level of mTOR and 4E-BP1 phosphorylation, commensurate with the obser-
vation that autophagy is maximally activated in the absence of survival signals.
4.3.3 Pathways regulating autophagy in human SLE
Finally, to attempt to determine the underlying basis for activation of autophagy in
SLE B cells, I analyzed the phosphorylation state of key signaling proteins relevant
to the regulation of autophagy using ﬂow cytometry, antibody coated bead array
(Luminex), and a phospho-speciﬁc AMPK ELISA.
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Figure 4.11: mTOR is activated following B cell stimulation in vitro. Healthy B
cells were stimulated with goat anti-IgM F(ab´)2 fragment (5μg/ml)
and monoclonal mouse anti-CD40 (1μg/ml) for 24 hours, then lysed
in the presence of phosphatase inhibitors. Immunoblotting was then
performed with the indicated antibodies. Experiment representative of
two independent replicates.
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4.3.3.1 Phospho-epitope speciﬁc ﬂow cytometric analysis of protein
phophorylation
For the ﬂow cytometric assay, PBMCs from patients with SLE and healthy con-
trols were isolated, and surface stained to discriminate between naïve, memory,
and plasmablast B cell subsets, then intracellular staining using phospho-speciﬁc
antibodies was performed.
Using the phospho-speciﬁc antibodies in table 4.3.3.1, I found no statistically sig-
niﬁcant difference between the B cells of patients with SLE and healthy controls, in
either in the total B cell pool, or by subset (ﬁgure 4.12), albeit in small sample sizes.
4.3.3.2 Phospho-AMPK ELISA
Next, I assessed the phosphorylation status of AMPK at Thr172, in total B cell lysates,
using a phospho-speciﬁc ELISA. AMPK is phosphorylated by LKB1 at Thr172 in re-
sponse to an increase in intracellular AMP and ADP, with decreasing ATP61. Phos-
phorylation at Thr172 activates AMPK, which may then subsequently phospho-
rylate ULK1 and thereby induce autophagy5. The antibody used in the ELISA is
speciﬁc for AMPK phosphorylated at Thr172. I found no signiﬁcant difference in
Thr172 phosphorylation in SLE patients compared with controls (ﬁgure 4.13). The
level of optical density was very low in both groups.
4.3.3.3 Luminex assay of protein phosphorylation
To quantify phosphorylation of proteins with the potential to regulate autophagy in
B cell lysates treated with phosphatase inhibitors, I employed a magnetic-bead cou-
pled Luminex panel to measure the phosphoproteins listed in table 4.4. In addition
to the phosphorylated protein, the total unphosphorylated protein was also mea-
sured, allowing the calculation of a ratio of phosphorylated to total protein. Using
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Table 4.3: Signaling pathways analyzed using PhosFlow
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Figure 4.12: Analysis of signaling in SLE vs. healthy control B cells by Phos-
Flow. A. The total CD19+ B cell pool was analyzed for the phospho-
rylated proteins listed in table 4.3.3.1. B-D. B cell subset speciﬁc anal-
ysis of phospho-Akt (Ser473) (B), phospho-S6K1 (Ser235/6) (C), and
phospho-Bcl-2 (Ser70) (D) in CD19+CD27- naïve, CD19+CD27+ mem-
ory, and CD19+CD27++ plasmablast B cells. Each point represent an
individual patient or control.
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Figure 4.13: ELISA of phospho-AMPK (Thr172) in SLE B cell lysates compared
with healthy controls. Freshly isolated total C19+ B cells were lysed in
the presence of phosphatase inhibitors. Each point represents an indi-
vidual patient or control. The mean is shown. Mann-Whitney U test
used.
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Table 4.4: Analytes in Luminex assay of protein phosphorylation
this assay, I found that there was signiﬁcantly more phosphorylation of GSK3α/β in
SLE compared with healthy controls, expressed as a ratio (ﬁgure 4.14). If phospho-
rylated protein alone is compared, there were also statistically signiﬁcant increases
in phospho-Akt and phospho-p70S6K1.
4.4 Discussion
The chapter describes the application of novel tools for the analysis of autophagy
in ex vivo lymphocytes, for the study of autoimmune disease.
The differential activation of autophagy in SLE B cells is a novel ﬁnding. Notably,
the largest increase in autophagosomotropic dye uptake and the lowest level of p62
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Figure 4.14: Phosphoprotein assay of A. Akt (Thr308), B. GSK3α/β (Ser9/21), and
C. p70S6K (Thr421/Ser424) in SLE B cell lysates. Freshly isolated to-
tal C19+ B cells were lysed in the presence of phosphatase inhibitors.
n=10 per group. Error bars denote SEM. Unpaired t test  used for
comparisons.
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Figure 4.15: Phosphoprotein  assay  of  A.  p38  MAPK (Thr180/Tyr182)  and  B.
ERK1/2 (Thr202/Tyr204, Thr185/Try187). n=10 per group. Error bars
denote SEM. Unpaired t test used for comparisons.
is in the CD27-IgD- subset, with lesser increases in memory B cells (CD27+). Inter-
estingly, there was no difference in plasmablasts, if the CytoID MFI was expressed
in terms of a ratio to FSC. A difference in autophagy between B cell subsets within
the healthy control subjects was also apparent, with relative increases in the CD27-
population compared with CD27+ and CD27++ cells.
The CD19+CD27-IgD+ population identiﬁed as that with maximal autophagy in-
cludes principally naïve, but also transitional B cells, populations with speciﬁc and
separate survival requirements and characteristics from memory B cells and plas-
mablasts. In SLE, this population (CD19+CD27-) of naïve B cells is reduced, in
contrast to a relatively normal memory compartment and an increased number of
CD27++ plasmablasts156. Underlying mechanisms for this naïve B cell lymphopenia
have not been established.
Multiple possibilities exist for the ﬁnding of activated autophagy in naïve B cells,
and may be classiﬁed into three broad categories.
101
4 Assessment of autophagy in human SLE
4.4.1 Autophagy as a mechanism for the survival of autoreactive B
cells
As has been outlined above, a tolerance checkpoint exists as transitional B cells com-
plete their development into naïve B cells, and which has been demonstrated by
single cell Ig cloning to be defective in SLE148. Whilst there is no signiﬁcant differ-
ence in autoreactivity between newly emigrant B cells from patients with SLE and
healthy controls, autoreactive B cells were enriched in the mature naïve B cell pool
in disease. In health, peripheral B cell survival is an outcome contingent on appro-
priate BCR stimulation, and access to survival factors, most notably BAFF. B cells
that receive stimulation through their BCR in excess of a threshold are rendered
anergic, a state characterized by down-regulation of surface IgM and inhibition of
antibody secretion274. Alternatively, high levels of BCR stimulation may induce
apoptosis, with consequent deletion of the autoreactive B cell167;275. This process
may be mediated by stimulation of the extrinsic pathway of apoptosis through in-
teraction between B cell CD95 and Fas-ligand on CD4+ T cells276, but principally
depends, as mentioned above, on adequate BAFF exposure277;278. BAFF and its
homologue A Proliferation Inducing Ligand (APRIL) are members of the TNF fam-
ily, and are secreted by innate immune and stromal cells, the activation of which
leads to the cleavage and secretion of the transmembrane forms of these proteins191.
BAFF and APRIL have differences in receptor binding; BAFF-R (BAFF receptor) is
speciﬁc for BAFF, whereas B cell maturation antigen (BCMA) and transmembrane
activator and calcium modulator ligand interactor (TACI) may bind both BAFF and
APRIL. BAFF-R signals through two major pathways: PI3K-Akt-mTOR, and NF-
κB191. BAFF stimulation activates mTORC1279, which as described in ??, leads to
cell anabolism and proliferation, and inhibits autophagy. Furthermore, Akt signal-
ing inhibits the pro-autophagic transcription factor FOXO3a. However, levels of the
BH3 family member Bim are reduced, which promotes autophagy as its inhibitory
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interaction with beclin-1 is suppressed280. Bim appears to play a critical role in the
death of autoreactive B cells, as deﬁciency of this protein leads to autoimmunity151.
To date, the effect of genetic activation of autophagy on autoimmunity has not
been examined. However, Atg5 and Atg7-overexpressing transgenic mice on non-
autoimmune backgrounds have enhanced lifespans and are not reported to develop
features suggestive of immune-mediated disease281;282. These relatively prelimi-
nary ﬁndings imply that autophagy over-activation is not in itself sufﬁcient to in-
duce autoimmune disease. These data are somewhat surprising given the impor-
tance of autophagy throughout the immune system, and further study of the prop-
erties of these mice is likely to be of great interest, particularly in the context of
infectious disease.
4.4.2 Autophagy as a reﬂection of B cell activation
Given that SLE is associated with B cell hyperactivation, could this account for the
observed up-regulation of autophagy? The extent to which autophagy is activated
or suppressed following stimulation in B cells is not entirely clear, and may depend
on accompanying survival signaling. It has been observed by Watanabe et al. that in
murine primary B cells, BCR stimulation activates autophagy, probably as a prelude
to apoptosis, but when CD40 is co-ligated, autophagy is suppressed237. Signaling
through TLR4 or TLR9 has been demonstrated to activate autophagy238;240. It seems
probable that in SLE, activated B cells that have not yet received co-stimulation and
are therefore at risk of apoptosis, may up-regulate autophagy and contribute to-
wards the observed results. The in vitro results I have obtained (4.3.2) are contrary
to those of Watanabe et al., but support the hypothesis that autophagy may act as
a survival mechanism for threatened B cells. Mechanistically, I have demonstrated
the activation of mTOR signaling following B cell stimulation, which is agreement
with the observed reduction in autophagy following growth signaling. In fact, it is
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difﬁcult to reconcile mTOR signaling following differentiation and growth stimuli
with autophagy activation, as reported237;238;283. One interesting explanation how-
ever, might be that mTOR signaling and autophagy regulation become detached,
with activation of both pathways serving to support high levels of protein synthe-
sis. Narita et al. have demonstrated that this phenomenon may occur in the speciﬁc
sub-cellular location they termed the TOR-autophagy spatial coupling compart-
ment (TASCC)284. It is possible therefore that the TASCC may operate as B cells
differentiate to secrete immunoglobulin. My in vitro B cell stimulation experiments
were over a relatively short time-course (up to 48 hours), and it may be that the
TASCC is not yet active. One further issue is that I have only used one assay of au-
tophagy (CytoID), and have not examined ﬂux. Further work is therefore required
to allow more conclusive account to be made of the role of autophagy in early B cell
activation.
4.4.3 Autophagy as a mechanism for presentation of self-antigens
A remaining hypothetical role for autophagy in the pathogenesis of SLE is that its
up-regulation, perhaps in the contexts discussed above, may enhance or lead to the
presentation of self-antigens on MHC-II by B cells. Whilst this question has not been
addressed by my experimental work, there is supporting literature that is sugges-
tive of this possibility. Autophagy has been demonstrated to be required for antigen
presentation on MHC-II by dendritic cells, and has an important function in cross-
presentation of endogenous antigens200;213;216. Notably, stimulation of autophagy
increases the display of nucleus-derived antigens. It also enhances the immune re-
sponse to intracellular organisms e.g. HSV and TB in vitro and in vivo200;217. Finally,
in tumour cells, activation of autophagy by chemotherapeutic agent-induced cell
stress leads to the release of ATP, thereby enhancing recruitment of T cells285.
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4.4.4 T cells
The increased autophagosome density in the total CD4+ T cell pool is in agree-
ment with the work of Gros et al., who observed increased autophagosome den-
sity by electron microscopy in the T cells of SLE patients compared with healthy
controls247, but differs from the results of Alessandri et al., who detected differen-
tial autophagy only in the naïve T cell subset248, rather than the entire CD4+ T cell
population. Methodologically, Gros et al., Alessandri et al. and I all used differing
techniques to quantify autophagy, which may to some extent account for the dis-
crepant results. Due to the relative novelty of my ﬁndings in B lymphocytes, further
experimental work concentrated on this cell type, and so the ﬁndings in T cells is
therefore largely preliminary. Speciﬁcally, I have not performed a ﬂux assay and so
it is possible that the signiﬁcantly increased autophagosome count may result from
impaired autophagosome-lysosome fusion. It is noteworthy that I did not detect a
difference in p62 levels in SLE CD4+ T cells.
In common with the clinical experimental data from B cells, the role of T cell au-
tophagy in the pathogenesis of SLE must remain largely speculative, and the extent
to which its distinct functions contribute to disease on a differential basis is un-
known.
4.4.5 Regulation of autophagy in SLE
Whilst I have outlined hypotheses that might explain the observed activation of
autophagy in SLE, how might this be regulated? In the results presented in 4.3.3, I
have examined a number of signaling pathways known to inﬂuence autophagy, by
detecting protein phosphorylation in either intact cells by ﬂow cytometry, or in B
cell lysates. Using a Luminex-based suspension array system, I found that the ratio
of phosphorylated:total GSK3 was signiﬁcantly increased in SLE compared with
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healthy controls. There were also relative increases in the total and phosphorylated
forms of Akt and p70S6K1, but the phosphorylated:total ratio was not signiﬁcantly
different. GSK3 is a serine/threonine protein kinase which is constitutively active
in basal conditions, as described in ??. Phosphorylation of GSK3 at Ser9 for the β-
isoform, and at Ser21 for the α-isoform, leads to inactivation of GSK3 and therefore
transcription factor dephosphorylation and activation. The function of the GSK3
signaling pathway in the regulation of autophagy is unclear, and the conﬂicting
literature outlined in ?? suggests that a degree of cell type speciﬁcity may exist.
GSK3 signaling has not been examined in SLE before and this result is therefore a
novel ﬁnding.
Using an ELISA for the phosphorylated form of AMPK (Thr172), I was unable
to detect a difference between SLE and healthy control freshly isolated B cells, in a
small sample set. Whilst this negative ﬁnding may simply represent a type II error
or true result, the degree of phosphorylation was very low in both groups, sug-
gesting the possibility of technical experimental failure, interference during sample
processing, or that a signiﬁcant difference may only be revealed following stimula-
tion.
The data obtained from the PhosFlow experiments is hampered by two poten-
tial issues: phosphatase activity, and small sample sizes. Samples were stored
overnight at 4ºC in PBS before permeabilization with a saponin-containing buffer
and intracellular staining the following day. During this time period there is sig-
niﬁcant potential for intracellular phosphatase activity which would result in loss
of target phosphorylation and thus experimental signal. This shortcoming needs to
be addressed by the use of a phosphatase inhibitor (as used during cell lysis), and
staining before cell storage, or selection of an alternative permeabilizing agent e.g.
methanol which prevents phosphatase activity.
The pathways assayed are not exhaustive and it is unknown to what extent rela-
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tive levels of phosphorylation of key proteins regulate autophagy in sum. Although
it is probable that GSK3 signaling may tend to inhibit autophagy, it is possible that
this activation is counter-regulatory. The pro- and anti-apoptotic BH3 proteins also
require examination, as a potentially important regulator of autophagy in SLE. Sim-
ilarly, Foxo3 nuclear translocation may be assayed using MIFC.
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5.1 Introduction
In the preceding chapter, I have presented results demonstrating that autophagy
is activated in the CD19+ B and CD4+ T cell populations from patients with SLE.
Whilst these data are derived from human disease and are therefore of maximal
clinical relevance, they are subject to a number of shortcomings inherent in the study
of human SLE. These include, in probable order of maximum importance:
Confounding by therapy
The patients I have studied had all been subject to pharmacologic intervention,
including agents known to inﬂuence autophagy at high dose in vitro (e.g. pred-
nisolone and hydroxychloroquine). Whilst I found no statistical evidence of cor-
relation between drug use and markers of autophagy (table 4.3.1), the existence of
type II error cannot be fully excluded. Ideally, I would only include patients ei-
ther before, or on no, drug treatment; however in practice it is extremely difﬁcult to
recruit such subjects and it is therefore impractical over a reasonable timescale.
Limited access to the B cell compartment I was restricted to the collection of pe-
ripheral blood from both patients and healthy controls. Whilst naïve and memory
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B and circulating plasmablasts are sampled, B cells in the earlier stages of devel-
opment, and those undergoing the germinal centre reaction and plasma cells are
largely excluded from study. To capture these other populations, lymph node and
bone marrow sampling would be required, which again is impractical in the patient
pool from which I was able to recruit.
Clinical heterogeneity SLE is a disease that exhibits great clinical and immuno-
logic heterogeneity. Moreover, it is subject in many cases to signiﬁcant temporal
variation and typically follows a relapsing-remitting course. The complex multi-
factorial aetiology of SLE as discussed in chapter 1, accounts for this.
5.1.1 The NZB/W murine model of SLE
The study of a murine model of SLE largely overcomes these three considerations,
but with the major caveat that those available do not necessarily fully or accu-
rately recapitulate the human disease. The principal murine models of lupus are
the New Zealand Black × White F1 hybrid (NZB/W), the MRL/lpr mouse, and the
BXSB/Yaa286, all of which develop an ultimately fatal autoimmune disease charac-
terized by ANA and glomerulonephritis287.
The NZB/W model has more complete disease expression in female mice, with
a correspondent earlier mortality. The mean age for 50% and 90% of mice to have
succumbed is 8.5 and 12.5 months respectively287. NZB/W mice develop severe
glomerulonephritis with heavy proteinuria and C3 and IgG deposition. There are
not typically ANA until later than 2 months; anti-dsDNA antibodies appear from
5-6 months and progressively accumulate thereafter287. NZB/W mice also exhibit
lymphadenopathy, vasculitis, hypocomplementæmia, and immune complex for-
mation, notably with antibodies against the murine endogenous retrovirus protein
gp70287.
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Immunologically, the NZB/W mouse displays B cell hyperactivity, and this prop-
erty is intrinsic, as autoimmunity is induced in severe combined immunodeﬁciency
(SCID) mice transplanted with NZB/W pre-B cells288;289. The genetic basis for the
NZB/W phenotype is unknown, but it behaves as a complex trait with polygenic
inheritance290. The NZB/W derivative strains NZM2410 and NZM2328 contain the
susceptibility loci Sle1-3, mapped via linkage analysis. Congenic models containing
the Sle1 locus develop anti-chromatin antibodies, but the genetic interval incorpo-
rating this region is wide, and includes several smaller risk loci, inﬂuencing T and
B cell activation286;290. The Sle2 locus, again studied using congenic strains, is sim-
ilar structurally, containing many separate risk genes, which lead to lower B cell
activation thresholds and increased numbers of B1a B cells291.
In this chapter, I use the NZB/W model to study autophagy in murine SLE, both
before and after the onset of disease.
5.2 Aims
To determine autophagy in the NZB/W murine model of SLE, in pre- and post-
disease mice
5.3 Results
5.3.1 Autophagosome density is increased in NZB/W B cells
To determine autophagosome density in splenic lymphocytes, MIFC was employed,
using immunoﬂuorescent detection of endogenous LC3. Female NZB/W mice were
sacriﬁced at 13 weeks of age, and compared with sex and age matched C56BL/6 (B6)
control mice.
As in the analytic approach performed on ex vivo human cells, the Spot Count
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algorithm was applied to detect LC3+ punctae, representing autophagosomes, in
splenic B cells. Figure 5.1 (A) illustrates examples of B cells with high and low spot
counts, and ﬁgure 5.1 (B) shows representative distributions of Spot count between
NZB/W mice and B6 controls. As in human SLE, the distribution was left-skewed
and therefore autophagy was quantiﬁed using an empirical deﬁning gate.
Using MIFC, I found more autophagosomes in NZB/W splenic B cells than in B6
controls (ﬁgure 5.1).
To conﬁrm this result using an alternative technique, I again utilized the autophago-
somotropic dye CytoID, the uptake of which was quantiﬁed using conventional
FACS (ﬁgure 5.2). To gain access to the full B cell compartment, spleen and bone
marrow was analyzed (ﬁgure 5.3).
The results from this experiment are in agreement with the MIFC data, demon-
strating increased autophagosome density in NZB/W splenic B cells, deﬁned broadly
as CD19+. In contrast to the results in humans with SLE however, I did not ﬁnd
increased dye uptake in CD4+ T cells, albeit using a different experimental method-
ology. Extending the analysis across wider B cell phenotyping, there are two major
observations.
Firstly, autophagosome density is generally increased in bone marrow B cells,
compared with peripheral cells, in both diseased and control mice. Secondly, dif-
ferential dye uptake was maximal in relatively less mature B cells (i.e. bone marrow
stages). Speciﬁcally, differences were greatest in pre-B, immature B, and mature B
cells (deﬁned as CD19+IgD-IgM-, CD19+, IgD-IgM+, and CD19+IgD+IgM+ respec-
tively) in the bone marrow. In the periphery, transitional T1 (CD19+IgD-IgM+CD23-CD21-)
and T2 (CD19+IgD+IgM+CD23+CD21+) B cells displayed greatest relative autophago-
some density. Interestingly, and mirroring human data, there was less autophagy
in plasma cells in NZB/W mice compared with B6 controls.
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Figure 5.1: Autophagy in murine lupus quantiﬁed by MIFC. Autophagy in splenic
NZB/W CD19+ B cells was compared with control B6 mice. A. Repre-
sentative MIFC images of B cells with high and low numbers of LC3+
autophagosomes. B. Example distributions of LC3+ punctae in diseased
vs. control mice at 13 weeks of age, with gating of autophagy-positive
cells (deﬁned as ≥7 spots per cell). C. There are increased numbers of
LC3+ autophagosomes in the CD19+ B cells of NZB/W compared with
control mice at 13 weeks (post-disease onset). Each point represents an
individual mouse. C. Mann-Whitney U test used
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Figure 5.2: Autophagy in murine lupus quantiﬁed by CytoID uptake. A. CD19+ B
and B. CD4+ T cells. Each point represents an individual mouse. Mann-
Whitney U test used.
5.3.2 Autophagic ﬂux is active in NZB/W B cellstrend
As has been described above (4.3.1.1), to exclude a defect in autophagosome-lysosome
fusion, it is necessary to employ an assay that reveals autophagic ﬂux. In this ex-
periment, p62 levels were quantiﬁed by intracellular FACS following incubation of
cells in complete RPMI media supplemented with baﬁlomycin A1 for 3 hours. p62
is an autophagosome adapter protein mainly cleared by autophagy, and whose lev-
els are inversely correlated with autophagic activity. Blockade of autophagosome-
lysosome fusion would, in the context of active ﬂux, therefore lead to an increase
in p62 levels. I found signiﬁcantly decreased basal p62 levels in both the total
peripheral CD19+ pool, and a non-statistically signiﬁcant trend to a decrease in
CD19+/-CD138+ splenic plasma cells (ﬁgure 5.4). For the baﬁlomycin A1 ﬂux ex-
periment, splenic CD19+ B cells were examined. I found an increase in p62 levels
following the incubation period, indicating accumulation of autophagosomes and
therefore active autophagic ﬂux.
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Figure 5.3: Autophagosome  density  in  mouse  B cell  subsets. Distri-
bution  of  CytoID MFI in  B cell  subsets  from  bone  marrow
and  spleens  of  13  week-old  NZB/W mice  and  age  matched
controls. Pre-B (CD19+IgD-IgM-), immature  B (BM Imm,
CD19+IgD-IgM+), mature  B (BM Mat, CD19+IgD+IgM+), T1
(CD19+IgD- IgM+CD23-CD21-), T2  (CD19+IgD+IgM+CD23+CD21+),
marginal  zone  (MZ,  CD19+IgD-IgM+CD23-CD21++), follicular  (FO,
CD19+IgD+IgM-CD23++CD21+), and  bone  marrow  plasma  cell
(CD19+/-CD138+) subsets are illustrated. n=5 mice per group. Box
and whisker plots denote maximum and minimum, interquartile range,
and median. *p<0.05; **p<0.01; ***p<0.001. ANOVA used for analysis.
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Figure 5.4: p62 dynamics in ex vivo NZB/W and B6 B cells. A. There is decreased
basal p62 expression, measured by intracellular FACS in splenic CD19+
B cells, and a trend towards a reduction in CD19+/-CD138+ plasma cells
(PC) in 13 week-old NZB/W mice. B. To demonstrate accumulation
of the autophagic substrate p62, isolated splenocytes were incubated in
complete RPMI with 100nM baﬁlomycin A1 for 3 hours. n=5 mice per
group. Fold change in p62 MFI compared with untreated cells is shown.
C&D. There is good inverse correlation between p62 levels and CytoID
uptake (C). A-B: Mann-Whitney U test used, C: Pearson’s correlation.
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Figure 5.5: Autophagy before and after the onset of disease in B cells of NZB/W
mice. The number of autophagosomes measured using MIFC (A) or au-
tophagosomotropic dye (B) increases with age, but a difference between
the mice is present even at 4 weeks, before disease has developed. Un-
paired t test used for comparisons.
5.3.3 Autophagy is activated even before the onset of disease in the
NZB/W mouse
I next went on to determine the temporal relationship between the onset of disease
and the activation of autophagy in the NZB/W mouse. To do this, NZB/W mice
were compared with age matched B6 controls at 4 and 28 weeks of age; that is, in
pre-disease and established disease. Autophagy was determined in splenic CD19+
B cells using MIFC and CytoID assays (ﬁgure 5.5). I found that autophagy was dif-
ferentially enhanced in the NZB/W mouse even at 4 weeks, and remained elevated
to a similar degree at 28 weeks. In the B6 mice however, there was an increase in
autophagosome density from 4 to 28 weeks of age, more clearly appreciated by the
CytoID assay.
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5.4 Discussion
The results described in this chapter demonstrate that autophagy is also activated
in the B cells of a murine model of SLE, and provide a more detailed assay of the
response of individual subpopulations within the broader B cell pool. It also re-
veals an increase in autophagosome density in the early, bone marrow stages of B
cell development compared to more mature peripheral cells, in both healthy and
diseased mice. The ﬁnal key ﬁnding is that autophagy is activated at an early stage
of development in the NZB/W mouse, before the onset of disease.
5.4.1 Activation of autophagy in the early stages of B cell
developmenttrend
The direct observation of activation of autophagy in the early stages of B cell de-
velopment is a novel ﬁnding, but one that is supported by existing data. Beclin-1
expression, detected using a beclin-1-GFP transgenic reporter mouse, is increased
in pro-B cells relative to pre-B and immature B stages225. Activation of autophagy
at this transition is commensurate with the phenotype of B cells deﬁcient in key au-
tophagy genes, e.g. Atg5 and beclin-1, which are characterized by a block in devel-
opment at the pro- to pre-B stage221;232. There are a number of possible explanations
for this ﬁnding. Firstly, the role of Bcl-2 in B cell development will be considered.
Bcl-2 is highly expressed in pro-B cells, but down-regulated at the pre-B and imma-
ture B stages234. This transition is associated with signiﬁcant physiological loss of B
cells, with approximately 75% of precursors failing to progress from pro-B to pre-B
cells142. At the pre-B stage, the newly rearranged heavy chain is paired with a surro-
gate light chain, to form the pre-BCR. Successful formation of a pre-BCR is vital for
cell proliferation and the development of a normal B cell compartment292. Autore-
active pre-BCRs are eliminated by mechanisms that have not been fully elucidated,
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but may include binding of self-antigens to the complementarity determining re-
gions (CDRs) of the newly rearranged heavy chains, or by defective association
with surrogate light chains293. I hypothesize that one mechanism for the activa-
tion of autophagy is this down-regulation of Bcl-2 expression, liberating beclin-1
and thereby initiating autophagosome formation. Autophagy may, in this circum-
stance, provide an important means for B cell survival when deletion is threatened.
Secondly, it is possible that autophagy may act as a support mechanism for with-
standing cellular stress incurred by DNA damage during the action of DNA en-
donucleases. Rag1/2 expression begins at the Pro-B stage, with rearrangement of
the IgH locus. Rag1/2 is then down-regulated by signals from the pre-BCR and by
IL-7, forcing allelic exclusion, then re-expressed to allow IgL rearrangement294. The
formation of double-stranded breaks (DSBs) by Rag leads to phosphorylation of
ataxia telangiectasia mutated (ATM) kinase, which both phosphorylates many com-
ponents of the DNA damage response, and also directly stabilizes the DSBs295;296.
ATM activates autophagy via LKB1 mediated phosphorylation of AMPK, which in
turn also inhibits mTORC1 signaling through TSC2297. Foxo3a is also up-regulated
during DSB formation, and interacts with ATM298. Interestingly, during pre-B de-
velopment, IL-7 signaling must be attenuated for Rag re-expression and IgL rear-
rangement to occur, and this event is associated with up-regulation of Foxo3a due
to suppression of Akt signaling299;300. It could be inferred therefore, that autophagy
is activated in this circumstance.
One signiﬁcant omission from the data collected on autophagy in the bone mar-
row is that the phenotyping panel did not include markers for pro-B cells. This
unfortunately to an extent limits the ability of my results to support the hypotheses
outlined above. The study of autophagy with more detailed bone marrow B cell
immunophenotyping is therefore clearly warranted.
Following egress from the bone marrow, there is a global reduction in B cell Cy-
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toID uptake, commensurate with a decrease in autophagy. This may be explained
by the conclusion of the process of receptor formation and testing, and the emer-
gence into maturity. Within the peripheral B cell pool, there are subset speciﬁc dif-
ferences in autophagy. Notably, there was signiﬁcantly more CytoID uptake in
marginal zone (MZ) than follicular (FO) B cells. MZ B cells are a population of
innate-like lymphocytes located at the splenic MZ, and in contrast to FO B cells,
typically have a polyreactive BCR, analogous to a TLR301. MZ B cells are respon-
sible for the T-independent adaptive immune response, and because they express
high levels of TLRs, are able to respond rapidly to infection through dual receptor
ligation, which leads to the production of high levels of low speciﬁcity immunoglob-
ulin302. MZ B cells are also a major source of natural immunoglobulin, important
in clearance of damaged and dead cells. Many of these functions may be associated
with activation of autophagy. However, it appears that autophagy is redundant in
the formation of MZ B cells, as Atg5-/- mice do not have a signiﬁcant difference in
this population compared with the wild-type232.
There is a degree of discordance in the data however, in the case of plasma cells.
Using CytoID, I found higher uptake in these cells than the remainder of the pe-
ripheral B cell compartment in the control mice, but interestingly in the NZB/W
mice, this differential was not present. However, in contrast, the expression of p62
in plasma cells was in fact higher in both control and diseased mice. One potential
explanation for this ﬁnding may indicate the limitation of p62 as a universal marker
of ﬂux. Plasma cells are subject to profound cellular stress caused by their extremely
high output of immunoglobulin. This leads to activation of the UPR, which is asso-
ciated with increased expression of p62, performing its role as a ubiquitin binding
protein303. In this situation therefore, p62 levels may be elevated due to transcrip-
tional regulation, limiting its utility as a marker of autophagy.
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5.4.2 Pre-disease activation of autophagy in the NZB/W mouse model
of SLE
A novel ﬁnding from the data presented in this chapter is that autophagy is en-
hanced in the B cells of the NZB/W mice, notably even before expression of dis-
ease. Much of the discussion applicable to this observation has been outlined in
chapter 4. However, the apparently intrinsic activation of autophagy in the pre-
disease mice will be considered further, as will the stage-speciﬁc ﬁndings. As has
been described above, the genetic abnormalities leading to the disease phenotype
of the NZB/W mouse are associated with B cell hyperactivation. How autophagy
may be enhanced is not clear. A study of the expression and phosphorylation state
of pathways associated both with activation and inhibition of autophagy has been
conducted in congenic mice carrying the Sle1-3 alleles304. There is phosphoryla-
tion of Bcl-2, which leads to its dissociation from beclin-1 and therefore initiation
of autophagy273. However, mTOR is also activated, which would tend to suppress
autophagy. The relative importance and net effect of these pathways is unclear.
The maximal differences in autophagy are seen in the bone marrow, in the pre-,
immature, and mature B cell stages. It is possible, as has been described, that in-
trinsic activation of autophagy allows autoreactive B cells to survive receptor testing
and to enter the periphery (ﬁgure 7.1. It is also possible that differential activation
of autophagy reﬂects the stress response to receptor editing in cells that have gen-
erated an autoreactive BCR. However, the currently available data cannot conﬁrm
or refute these hypotheses.
5.4.3 Limitations
As was outlined in the introduction to this chapter, the use of a model system elim-
inates many of the potentially confounding factors inherent to the study of human
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disease. The similarity of the results obtained in patients to the NZB/W mice sug-
gests that the human data is not skewed by the possible biases listed above. How-
ever, there is discrepancy between the results obtained in CD4+ T cells; using MIFC
in SLE patients, there was found to be higher autophagosome density in these cells,
whereas in the NZB/W mice, using CytoID, there was no difference between the
diseased and control mice. The latter ﬁnding is discordant with the results pub-
lished by Gros et al.247. Autophagy was determined by different experimental tech-
niques in all cases, and therefore direct comparison, given only one assay, must be
undertaken with a degree of caution.
One ﬁnal limitation that must be raised is that, owing to limited sample avail-
ability and the requirement for relatively complex immunophenotyping, the bone
marrow data that I have presented uses only one methodology for the determina-
tion of autophagy. It is therefore also not possible to exclude a defect in autophagic
ﬂux. Further work should thus include multimodal analysis of autophagy in de-
veloping B cells.
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6.1 Introduction
In the foregoing experiments, I have demonstrated activation of autophagy in the
B cells of humans and mice with SLE, with notable ﬁndings in the early, bone mar-
row stages of development. I next examined the requirement for autophagy in the
formation of antigen-secreting plasma cells.
Plasma cells are required to produce very high quantities of immunoglobulin, and
in order to do so acquire a number of specialized adaptations during differentiation.
The differentiation programme of plasma cells involves extinguishing expression of
genes associated with cell division and growth, and activation of the UPR, whilst
increasing the capacity of the protein synthesis machinery305;306.
The UPR is a conserved mechanism for the transduction of ER stress, activated
when the protein folding capacity of the ER is exceeded. The status of the ER is de-
tected by three principal sensors: activating transcription factor 6 (ATF6), protein
kinase RNA-like endoplasmic reticulum kinase (PERK), and inositol-requiring pro-
tein 1α (IRE1α). Activation of these sensors by misfolded proteins triggers two ma-
jor waves of response. The ﬁrst series of effects are the suppression of protein trans-
lation through phosphorylation of eukaryotic translation initiator factor 2α (eIF2α)
by PERK307}, an increase in mRNA decay mediated by IRE1α308, and activation of
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autophagy by JNK, again by IRE1α, and also by activating transcription factor 4
(ATF4) and C/EBP homologous protein (CHOP), downstream of PERK309;310. The
second wave of the UPR is characterized by initiation of a broad gene expression
program by the transcription factors X-box binding protein-1 (XBP1s), ATF4, and
ATF6f, leading to up-regulation of endoplasmic reticulum-associated decay (ERAD)
components, thereby enhancing the capacity of the ER to handle defective pro-
teins311. The role of autophagy in the persistent UPR is less clear, with some data
suggesting that XBP-1s (the active form of XBP-1) in fact down-regulates autophagy,
in least in neurons312.
6.1.1 The Atg7Flox/Flox-Vav-Cre mouse
To address the importance of autophagy in plasma cell formation, I utilized the
Atg7Flox/Flox-Vav-Cre mouse313. This mouse, denoted as Vav-Atg7-/-, was created by
crossing Atg7Flox/Flox with Vav-iCre mice, resulting in conditional deletion of Atg7313.
The Atg7Flox/Flox mouse is produced on a C57BL/6/CBA background, and the Vav-
iCre mouse is produced on a C57BL/6 background.
Atg7 has an E1-like function, activating Atg12 for conjugation with Atg512, and
is essential for autophagosome elongation. However, because knockout of critical
autophagy genes is lethal, it is necessary to use a tissue speciﬁc deletion model for
the study of autophagy deﬁciency in vivo314;315. The conditional knockout system
employed in the Vav-Atg7-/- mouse uses Cre-Lox recombination, excising the loxP
ﬂanked Atg7 gene with Cre recombinase under the control of the promoter for the
proto-oncogene Vav316. Vav transduces signals from a number of surface receptors
for Rho GTP binding proteins, and is expressed by all haematopoietic cells317;318.
Atg7 is therefore deleted in all cells of the immune system in the Vav-Atg7-/- mouse.
The Vav-Atg7-/- mouse has already been characterized in detail, and both efﬁcient
deletion of Atg7 and severe functional impairment of autophagy has been demon-
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strated313. The phenotype of the Vav-Atg7-/- mouse is of progressive bone mar-
row failure, with mortality typically occurring by 12-weeks. There is lymphopenia
for CD4+ and CD8+ T cells, and B cells. Vav-Atg7-/- T cells have increased active
caspase-3 staining, indicating apoptosis, and increased mitochondrial density with
higher levels of mitochondrial superoxide313. A major cause of the cytopenia ob-
served in this model is the dependency of haematopoietic stem cells on autophagy
for maintenance and self-renewal86;233.
6.2 Results
6.2.1 There is abnormal B cell development in the Vav-Atg7-/- mouse
I ﬁrst examined the B cell pool of female 8-week-old Vav-Atg7-/- mouse, to establish
the degree of conformation of this model to other published work. Bone marrow
and splenic B cells were extracted and immunophenotyping performed using ﬂow
cytometry (ﬁgure 6.1).
The results I obtained were in close agreement with the reported phenotype of
autophagy deﬁciency232. In the bone marrow which was as described, hypocellu-
lar233, there was an excess of pro- or pre-B cells, with a substantially smaller pro-
portion of immature and mature B cells. The phenotyping panel unfortunately did
not include markers to differentiate between pro- and pre-B cells. However, in the
periphery, although B cell numbers were reduced233, there were normal propor-
tions of mature B cells in the spleen. This supports the data presented in chapter
5; that autophagy is primarily activated in the bone marrow during development,
but is down-regulated in the periphery once maturity is reached. T cells from the
Vav-Atg7-/- mouse have increased mitochondrial density. To determine if there are
similar ﬁndings in Vav-Atg7-/- B cells, I used the mitochondrial dyes Mitotracker
Deep Red and Mitotracker Green, measuring their ﬂuorescence by ﬂow cytome-
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Figure 6.1: CD19+ B cell populations in Vav-Atg7-/- mice. A&B. Percentage ma-
ture IgM+IgG+ B cells in bone marrow are markedly decreased in Vav-
Atg7-/- mice, with an increased proportion of Pre-B cells. However, in
the spleen, the percentages of mature B cells are similar (C&D). Repre-
sentative data from n=4 mice of each phenotype.
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Figure 6.2: Mitochondrial density in Vav-Atg7-/- B cells. There is higher mitochon-
drial mass in Vav-Atg7-/- B cells, measured by MitoTracker Deep Red
and Green (A) and (B), compared with control mice. n=5 per group.
Mann-Whitney U test used for comparisons.
try. These are carbocyanine-based probes that selectively stain mitochondria, dif-
fering in emission frequencies, and can therefore be used as markers of mitochon-
drial mass. I found increased mitochondrial density with both dyes in Vav-Atg7-/- B
cells compared with controls (ﬁgure 6.2).
6.2.2 Autophagy is required for normal plasmablast differentiation
6.2.2.1 Vav-Atg7-/- B cells do not efﬁciently form plasmablasts
Next, I determined the requirement for autophagy in the differentiation of B cells
to immunoglobulin secreting plasmablasts. B cells were isolated from the spleens
of female 8-week-old Vav-Atg7-/- and control litter mates using negative magnetic
bead selection. B cells were then stimulated with LPS and IL-4 for 72 hours to in-
duce differentiation into plasmablasts. Following the culture period, the propor-
tion of viable, CD138+ cells was determined. There was decreased viability in the
Vav-Atg7-/- cells, and substantially fewer plasmablasts were formed (ﬁgure 6.3). To
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further conﬁrm the deﬁcit in plasmablast differentiation, an ELISA was performed
to examine immunoglobulin production (ﬁgure 6.3B). There was signiﬁcantly less
IgM secreted into the supernatant of the Vav-Atg7-/- plasmablast culture. Little
class switching had occurred in either the Atg7-/- or the control experiment, and
there was no signiﬁcant difference in IgG production, which was modest in both.
6.2.3 Pharmacologic inhibition of autophagy in human B cells
prevents their differentiation into plasmablasts
Following on from the results obtained in the Vav-Atg7-/- mice, I next wished to
establish if human B cells were also dependent on autophagy for efﬁcient differen-
tiation. I used the selective class III PI3K inhibitor 3-MA to pharmacologically in-
hibit autophagy. B cells were isolated by negative magnetic selection from healthy
donors. In order to induce plasmablast differentiation, cells were stimulated ac-
cording to a protocol adapted from Jourdan et al319. B cells were stimulated with
the type B CpG ODN2006 in the presence of CD40 ligation with an anti-CD40 an-
tibody, and IL-10 and IL-15. Plasmablasts were deﬁned as CD19+CD38++. I found
that 3-MA at a 5μM concentration largely abrogated plasmablast formation in this
experimental system (ﬁgure 6.4 ). Whilst 3-MA is widely used as an inhibitor of au-
tophagy, it has been suggested that in some contexts it may actually act to stimulate
autophagy, via a dual inhibitory effect on class I PI3K320. To conﬁrm that 3-MA was
inhibiting autophagy in cultured human primary B cells, I stimulated isolated cells
from healthy human donors for 72 hours using the protocol described above in the
presence or absence of 3-MA (5μM). During the last hour of culture, baﬁlomycin
A1 was added to a concentration of 100nM. The addition of an autophagosome-
lysosome inhibitor served to enhance LC3 levels by inhibition of autophagic ﬂux,
thereby allowing easier immunodetection of this protein. The cultured cells were
lysed, and the ratio of LC3-II to β-actin determined using western blotting. I found
127

































Figure 6.3: Plasma cell differentiation is impaired in vitro in Vav-Atg7-/- B cells.
B cells  from Vav-Atg7-/- or  control  mice  were  stimulated  with  LPS
(10μg/ml) and IL-4 (10ng/ml) for 72 hours. Following the culture pe-
riod, there was signiﬁcant impairment of differentiation into plasma
cells in Vav-Atg7-/-B cells (A) compared with controls (B), and (C). Ac-
cordingly, there was less immunoglobulin secretion in the Vav-Atg7-/-
culture. Representative of 2 independent experiments, n=5 per group.
C. Mann-Whitney U test used for comparison.
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that 3-MA treatment reduced the level of lipidated LC3, indicative of inhibition of
autophagy (ﬁgure 6.5).
To determine to what extent 3-MA inhibited cell division, I examined dilution of
the dye CFSE by ﬂow cytometry. CFSE covalently binds to lysine residues within
the stained cell, and due to this attachment is stably retained. CFSE is therefore
distributed into daughter cells during division. There were fewer cell divisions in
the 3-MA treated cells than in the control, untreated culture (ﬁgure 6.4).
6.3 Discussion
6.3.1 Autophagy is required for the efﬁcient differentiation of
plasmablasts
The data I have obtained reveal that autophagy is required for plasmablast forma-
tion. The potential roles that autophagy might play in this process will now be
considered.
6.3.1.1 Autophagy and cell proliferation
Autophagy has a well-described modulatory effect on cell proliferation through its
effects on cellular energy metabolism. Interestingly, the extent to which cell types
are affected by loss of autophagy is variable, and in some circumstances it may
in fact promote tumorigenesis321. Reports of the effects of autophagy deﬁciency on
lymphocyte proliferation vary. Atg5-/- T cells have impaired division following TCR
stimulation or treatment with PMA and ionomycin223. However, Atg5-/- B cells have
been previously described as having essentially normal early in vitro proliferation in
response to LPS232;238. Whilst I did not examine Vav-Atg7-/- B cells, human B cells
treated with 3-MA exhibited a signiﬁcant reduction in division, as assessed by CFSE
dilution. Why differences between T and B cells should exist is not clear, but their
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Figure 6.4: Pharmacological inhibition of autophagy in human plasmablast dif-
ferentiation in vitro. B cells from healthy human donors were stimu-
lated with ODN2006 (5μM), IL-10 (50ng/ml), IL-15 (10ng/ml), and mon-
oclonal mouse anti-CD40L (1μg/ml) for 72 hours in the presence or ab-
sence of the autophagy inhibitor 3-MA (5μM). There was almost com-
plete inhibition of differentiation into CD19+IgD-CD38++ plasmablasts
(A-C), associated with impairment of cell division as assessed by CFSE
dilution (D&E). C. Mann-Whitney U test used for comparison.
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Figure 6.5: 3-MA inhibits autophagy in human B cells. B cells were stimulated
with the type B CpG ODN2006 in the presence of CD40 ligation with an
anti-CD40 antibody, and IL-10 and IL-15, with or without 5mM 3-MA,
for 72 hours. Baﬁlomycin A1 was added to a concentration of 100nM for
the ﬁnal hour of culture. A. Immunoblotting for LC3, representative of
2 independent experiments. B. LC3-II:actin ratio, n=2 per group.
metabolic demands may perhaps differ, e.g. cytokine production vs. endoplasmic
reticulum expansion.
6.3.1.2 Autophagy and plasmablast differentiation
Results generated in Vav-Atg7-/- and human B cells demonstrate that autophagy is
required for plasmablast formation. As described above, the importance of the UPR
in plasmablast function is well established. The UPR is associated with activation
of autophagy through JNK signaling, and the two pathways have signiﬁcant over-
lap in function. It is likely therefore that autophagy acts in concert with the UPR
to contain the cellular stress associated with immunoglobulin production. My data
demonstrates that following culture, there is signiﬁcantly less viability in the Vav-
Atg7-/- plasmablasts than in the control population. Many cell survival functions
performed by autophagy may explain this ﬁnding, and one of which I examined
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was mitophagy. There was higher mitochondrial density in the B cells of the Vav-
Atg7-/- mice, suggestive of disrupted mitophagy. Mitophagy is required for the
clearance of damaged and defective mitochondria, which would otherwise predis-
pose the cell to apoptosis40. It is therefore possible that this at least in part accounts
for the impaired viability observed in the autophagy deﬁcient cells.
During the production of the results presented in this chapter, two groups re-
ported largely similar ﬁndings, but with signiﬁcant differences in detail, both us-
ing the same CD19-Cre-Atg5Flox/Flox conditional knockout mouse model238;239. The
CD19-Cre-Atg5Flox/Flox mouse selectively deletes Atg5 in B cells, and therefore rel-
evant in vivo experimentation is possible, which is not the case in the Vav-Atg7-/-
mouse, which has autophagy deﬁciency throughout its immune system. Despite
this, however, the immunophenotype of the Vav-Atg7-/- mouse does appear to be
largely similar to the CD19-Cre-Atg5Flox/Flox, in that the mature B cell pool appears
to be proportionally normal. The numerical and likely functional deﬁcit in T cells
would be expected to limit the immune response to T-dependent antigens, render-
ing comparisons of terminal B cell differentiation difﬁcult.
Whilst Conway et al., Pengo et al. and I draw the same conclusion, that autophagy
is required for plasmablast differentiation; there are important variations in our re-
sults238;239. Conway et al. and I found that in vitro plasma cell development was
substantially impaired, with reduced antibody secretion following LPS stimulation.
However, Pengo et al. detected no difference in CD138+ cell proportion after a sim-
ilar culture period, and no defect in proliferation. Despite this discrepancy, they
found approximately twice the proportion of apoptotic cells in the Atg5-/- culture
versus the control, whereas Conway et al. detected no increase in apoptosis. Why
these differences should occur is not clear. All three experiments used different
concentrations of LPS (10 or 20μg/ml), and my culture was supplemented with
IL-4. It is possible that autophagy has varying importance dependent on the de-
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gree and nature of stimulation. It may also be the case that B cells isolated from
the Vav-Atg7-/- mouse, which has generalized dysfunction of the immune system,
may be inherently more susceptible to apoptosis and less amenable to plasmablast
formation, due to diminished cytokine support. Alternatively, Atg7 deletion may
lead to a phenotype distinct from Atg5 knockout, rather than generic autophagy
deﬁciency322.
Whilst I noted increased mitochondrial density in autophagy-deﬁcient B cells,
Pengo et al. found that mitochondria-associated proteins were not over-represented,
using stable isotope labeling in cell culture (SILAC) followed by mass spectrom-
etry. They did however, detect an increase in ER-resident proteins, and compo-
nents of the immunoglobulin molecule. Dye labeling of mitochondria, and mass
spectrometric identiﬁcation of mitochondria-associated proteins are very different
techniques, but apparently intact mitophagy in B cells would be a ﬁnding against
expectation.
There are further signiﬁcant differences in the ﬁndings of Conway et al. and
Pengo et al. Notably, Conway et al. detect substantially fewer plasma cells in the
bone marrow of CD19-Cre-Atg5Flox/Flox mice, whereas Pengo et al. ﬁnd no difference
compared with controls. The immunophenotyping strategies adopted by the two
groups are different, with Pengo et al. gating on IRF4+B220-CD138+, whilst Conway
et al. deﬁne plasma cells as CD19+CD138+. CD138 is also expressed during the pre-B
stage of B cell development, and so the former gating deﬁnition is to be favored323.
Interestingly, Conway et al. ﬁnd that serum immunoglobulin levels are not reduced
in the CD19-Cre-Atg5Flox/Flox mouse. Examining differences at the mRNA transcript
level, Conway et al. detected impaired expression of the transcription factors XBP-1
and PRDM1 in CD19-Cre-Atg5Flox/Flox B cells stimulated with LPS, whereas Pengo
et al. found that levels of these transcripts were in fact increased.
However, both authors agree that the antibody response to both TD and TI im-
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munization is impaired in the conditional knockout. In the TD response, processing
of the antigen by the B cell with subsequent presentation to its cognate CD4+ T cell
provides co-stimulation and leads to B cell proliferation. The TI response is inde-
pendent of T cell help, and is elicited by engagement of TLRs, or multivalent binding
of antigen to the BCR. The TI response does not lead to SHM or CSR. Interestingly,
Pengo et al. found that the antibody response to NP-Ficoll, a TI hapten that resists
clearance and leads to long-term production of immunoglobulin by B1a cells324,
was in fact enhanced in the CD19-Cre-Atg5Flox/Flox mouse. Why this should be the
case is not clear. Equally intriguingly, they also ﬁnd that immunoglobulin secre-
tion appears to be increased in autophagy deﬁcient B cells. Conway et al. detected
increased intracellular and surface immunoglobulin levels, but impaired secretion.
Overall, there is substantial variation in the details of the phenotype of murine B
cells deﬁcient in autophagy, with reconciliation of some of the experimental results
proving difﬁcult. Further work needs to be done to conﬁdently establish the role of
autophagy in B cell development and homeostasis.
134
7 Conclusions
In the work presented in this thesis, I have demonstrated activation of autophagy in
immune cells in SLE, notably in B lymphocytes, which represents a novel ﬁnding.
Similarly, the roles autophagy might play in B cell function have been relatively less
explored compared with T cells. For this reason, autophagy in B cells was speciﬁ-
cally chosen for more detailed study investigation. In order to overcome the limi-
tations imposed by small sample quantities available from diseased patients, novel
ﬂow-based assays were developed and utilized.
Examination of the peripheral B cell compartment in SLE indicates that autophagy
is principally enhanced in the naïve subpopulation. A potential explanation for this
observation is that autophagy is acting to sustain self-reactive B cells newly egressed
from the bone marrow, which would appropriately undergo apoptosis to avoid the
development of autoimmunity. To explore these ﬁndings more completely, I as-
sayed the central and peripheral B cell populations of the NZB/W murine model
of SLE, which allows exclusion of the potentially confounding variable of pharma-
cologic intervention, and also allows access to developing B cells in the bone mar-
row. The observations made in the peripheral B cell pool of the NZB/W mouse
recapitulated those in SLE patients, with autophagy activation prominent in less
mature cells. In the bone marrow, there were strikingly higher levels of autophagy
in developing B cells, with a greater differential between control and NZB/W mice.
Examining NZB/W mice of differing ages, I observed increased autophagy in the
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disease model even before the clinical onset of lupus. Finally, gaining insight into
the functional properties of autophagy, I noted a requirement for this process in the
efﬁcient differentiation of murine and human plasmablasts.
These results require explanation, and to determine the role of autophagy in the
pathogenesis of SLE, and in normal and autoreactive B cell development, much
more work needs to be done. Firstly, cause and effect need to be established in
the observation that autophagy is increased in SLE. The data I have collected so far
do not permit it to be concluded whether enhancement of autophagy is potentially
requisite to the development of disease, or if it is a reactive phenomenon driven
by threatened cell death. It is even possible that autophagy may be acting in some
capacity as a pro-cell death mechanism, thereby limiting autoimmunity. This ques-
tion may be resolved experimentally by the use of a model of SLE established in an
autophagy-deﬁcient background. Should modulation of autophagy prove to pre-
vent or reduce the severity of experimental SLE, then a strong argument would
be created for the trial of autophagy-modifying agents in human autoimmune dis-
ease. The detection of differential autophagy during B cell developmental stages in
both normal and diseased mice suggests as yet undeﬁned roles for this process in
B cell ontogeny. In murine models deﬁcient in autophagy in haematopoietic cells,
there is a developmental block at the pro- to pre-B cell transition, which is how-
ever surmountable, as there is a relatively normal peripheral mature B2 cell pool.
Conditional deletion of autophagy genes under the control of the CD19 promotor
is not however associated with early developmental defects, which is in keeping
with maximal activation of autophagy at the pro-B cell stage. This observation cor-
responds to equivalent ﬁndings in T cell development at the ’double negative’ thy-
mocyte stage. The seemingly speciﬁc nature of this block is interesting and does not
have an obvious explanation. The pro-B cell stage is associated with the recombina-
tion of the immunoglobulin heavy chain locus, which might, through the generation
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of DNA damage, recruit autophagy as a mechanism to counter stress. However,
since autophagy seems to be redundant at the pre-B cell stage, when light chain re-
combination occurs, it may be that signaling from the pre-BCR, aided by surrogate
light chains, provides the necessary survival stimulus and autophagy is no longer
required. This hypothesis, outlined in ﬁgure 7.1, again requires further investiga-
tion, as does the explanation for the difference in autophagy seen in the NZB/W
mouse model of lupus.
Autophagy may be modulated by a number of FDA approved pharmaceutical
agents, and therefore represents an interesting target for the treatment of autoim-
mune disease. Inhibition of autophagy may be one mode of action of hydroxy-
chloroquine in SLE, and this potential for rapid therapeutic translation is further















Figure 7.1: Autophagy in B cell autoimmunity. Following generation of an autore-
active surface Ig molecule, apoptosis is induced should editing fail. I hy-
pothesize that autophagy is activated and aids autoreactive cell survival.
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Table 8.1: Patient characteristics. ACR - American College of Rheumatologists.
HCQ - hydroxychloroquine, Pred - prednisolone, MMF - mycophenolate
mofetil, MTX - methotrexate
Patient Sex Age Diagnostic
Clinical
Features (ACR)
Antibodies C3/4 SLEDAI Medication





Low 10 Aza, Pred










Normal 4 MMF, HCQ





Normal 6 HCQ, Pred
189
8 Appendix
5 F 55 Arthritis, ANA,
Renal,
Haematologic
Anti-Ro Normal 4 Pred





Normal 8 MMF, Pred













Normal 5 HCQ, Pred






Normal 6 HCQ, Pred








Normal 0 MMF, HCQ
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Low 12 MMF, Pred







Normal 3 MMF, HCQ






Normal 1 MTX, HCQ





Normal 4 MMF, HCQ




ANA, Ro Low 10 MMF, Pred








Low 8 Pred, HCQ





Low 8 Aza, Pred, HCQ
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Low 8 Pred, HCQ




Normal 7 Aza, Pred, HCQ







Low 13 MMF, HCQ







Normal 6 MMF, MTX, Pred








Low 12 MMF, Pred





Low 12 Aza, Pred, HCQ
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Anti-Ro Low 11 Pred

















Low 14 Pred, MMF







29 F 44 ANA, Cerebral,
Arthritis,
Photosensitivity
N 0 Aza, Pred, HCQ







Low 8 Pred, MMF
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Low 6 MMF, Pred, HCQ







Low 12 MMF, Pred, HCQ
















Low 8 MMF, HCQ






Normal 8 MMF, Pred, HCQ
















Low 6 Pred, Mepacrine

























Low 8 HCQ, Pred







43 F 29 ANA, Discoid,
Mouth ulcers,
Arthritis,
Immunologic
Anti-
dsDNA
Low 9 HCQ
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